Deuterated compounds for restoring mutated p53 function
By developing compounds that can restore the DNA binding ability of mutant p53 protein, the problem of loss of mutant p53 protein in cancer has been solved, and effective inhibition and treatment of cancer cells has been achieved.
Patent Information
- Application Number
- CN202380028071.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-27
- Filing Date
- 2023-01-26
- Publication Date
- 2024-11-01
AI Technical Summary
Existing cancer treatment methods are difficult to effectively restore the wild-type function of the mutant p53 protein, resulting in the problem of uncontrolled cancer cell proliferation.
A compound that contains propynyl-substituted indolyl groups is developed that is able to selectively bind to the mutant p53 protein, restore its DNA binding capacity and activity, thereby activating downstream effectors and inhibiting cancer progression.
By restoring the activity of p53 protein, compounds can significantly increase the DNA binding ability and biological activity of p53 mutants, induce cell apoptosis, effectively inhibit the proliferation and division of cancer cells, and provide a new method for treating cancer.
Smart Images

Figure BDA0005045015980000021 
Figure BDA0005045015980000071 
Figure BDA0005045015980000101
Abstract
Description
[0001] Cross-references
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 303,535, filed on January 27, 2022, which is incorporated herein by reference in its entirety. Background Art
[0003] Cancer, i.e., uncontrolled cell proliferation, is a multifactorial disease characterized by tumor formation, growth, and in some cases metastasis. Cells carrying activated oncogenes, damaged genomes, or other changes that promote cancer can be prevented from replicating by an elaborate tumor suppressor network. A central component of this tumor suppressor network is p53, one of the most powerful tumor suppressors in cells. Both the wild-type and mutant conformations of p53 are implicated in the progression of cancer.
[0004] Incorporation by reference
[0005] Each patent, publication, and non-patent document cited in this application is hereby incorporated by reference in its entirety, as if each were individually incorporated by reference. Summary of the invention
[0006] In some embodiments, described herein is a compound comprising: a propynyl substituted indole group wherein one or more hydridos are replaced by a deuterium atom, wherein the compound binds to a mutant p53 protein and increases the wild-type p53 activity of the mutant p53 protein.
[0007] In some embodiments, described herein is a composition comprising a population of molecules, wherein the population of molecules has a mass of at least 1 μg, wherein at least 10% of the molecules in the population of molecules each independently comprise a deuterium atom, wherein each molecule is a compound of formula (Ia):
[0008]
[0009] in:
[0010] -R 1 selected from aryl, heteroaryl and heterocyclic groups, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the group consisting of hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic group, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R21 and ester groups;
[0011] -R 2 is an alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl group, each of which is independently unsubstituted or substituted with one, two or three substituents selected from the following:
[0012] hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R 21 and an ester group; or hydrogen, -C(O)R 21 、-C(O)OR 21 、-C(O)NR 21 R 22 、-OR 21 ,
[0013] -SR 21 、-NR 21 R 22 、-NR 21 C(O)R 22 or -OC(O)R 21 ;
[0014] -R 3 It is H;
[0015] -R 4 is a heterocyclic group substituted by one, two or three substituents selected from the group consisting of a halogen group, a hydroxyl group, a sulfhydryl group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group,
[0016] -P(O)R 21 and an ester group; and
[0017] - Each R 21 and R 22 is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclic, each of which is independently substituted or unsubstituted,
[0018] or a pharmaceutically acceptable salt thereof,
[0019] wherein said compound is optionally substituted with at least one deuterium.
[0020] In some embodiments, described herein is a method of inducing apoptosis in a cell, the method comprising contacting the cell with a therapeutically effective amount of a compound of the present disclosure that binds to a p53 mutant, wherein the compound increases the ability of the p53 mutant to bind DNA, wherein the cell expresses the p53 mutant.
[0021] In some embodiments, described herein is a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present disclosure.
[0022] In some embodiments, compounds that improve metabolic stability are described. DETAILED DESCRIPTION
[0023] The present disclosure provides compounds and methods for restoring the wild-type function of mutant p53. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA. The restoration of the activity of the p53 mutant can allow the activation of the downstream effectors of p53, thereby leading to the inhibition of cancer progression. The present disclosure further provides a method for treating a cancerous lesion or tumor with a p53 mutation.
[0024] Cancer is a family of related diseases characterized by uncontrolled cell proliferation with the potential for metastasis throughout the body. Cancer can be classified into five major categories, including, for example: epithelial cancers, which can arise from cells that cover internal and external parts of the body such as the lungs, breast, and colon; sarcomas, which can arise from cells located in bone, cartilage, fat, connective tissue, muscle, and other supporting tissues; lymphomas, which can arise in lymph nodes and immune system tissues; leukemias, which can arise in the bone marrow and accumulate in the bloodstream; and adenomas, which can arise in the thyroid, pituitary, adrenal, and other glandular tissues.
[0025] Although different cancers can manifest in almost any body tissue and contain unique features, the basic processes that lead to cancer can be similar in all forms of the disease. Cancer begins when cells escape the normal constraints on cell division and begin to grow and divide uncontrollably. Genetic mutations in cells can hinder the cell's ability to repair damaged DNA or trigger apoptosis, and can lead to uncontrolled growth and division of cells.
[0026] The ability of a tumor cell population to reproduce is determined not only by the rate of cell proliferation, but also by the rate of cell consumption. Programmed cell death, or apoptosis, represents the major mechanism of cell consumption. Cancer cells can evade apoptosis through a variety of strategies, such as by inhibiting p53 function, thereby inhibiting the expression of pro-apoptotic proteins.
[0027] Oncogenes and tumor suppressor genes can regulate the proliferation of cells. Genetic mutations can affect oncogenes and tumor suppressors, thereby potentially abnormally activating or inhibiting activity, further promoting uncontrolled cell division. Although oncogenes contribute to cell growth, tumor suppressor genes slow down cell division by repairing damaged DNA and activating apoptosis. Cellular oncogenes that can mutate in cancer include, for example, Cdk1, Cdk2, Cdk3, Cdk4, Cdk6, EGFR, PDGFR, VEGF, HER2, Raf kinases, K-Ras and myc. Tumor suppressor genes that can mutate in cancer include, for example, BRCA1, BRCA2, cyclin-dependent kinase inhibitor 1C, retinoblastoma protein (pRb), PTEN, p16, p27, p53 and p73. Tumor suppressor p53.
[0028] The tumor suppressor protein p53 is a 393 amino acid transcription factor that regulates cell growth in response to cellular stress, including, for example, ultraviolet radiation, hypoxia, oncogene activation, and DNA damage. p53 has various mechanisms for inhibiting cancer progression, including, for example, inducing apoptosis, maintaining genome stability, cell cycle arrest, inducing senescence, and inhibiting angiogenesis. Due to the key role of p53 in tumor suppression, p53 is inactivated in almost all cancers by direct mutation or by perturbations of related signaling pathways involved in tumor suppression. Homozygous loss of the p53 gene occurs in almost all types of cancer, including breast cancer, colon cancer, and lung cancer. In several types of human cancers, the presence of certain p53 mutations can be associated with less favorable patient prognosis.
[0029] In the absence of stress signals, p53 levels are maintained at low levels through the interaction of p53 with the E3 ubiquitin ligase Mdm2. In unstressed cells, Mdm2 can target p53 for degradation by the proteasome. Under stress conditions, the interaction between Mdm2 and p53 is disrupted, and p53 accumulates. The key event leading to p53 activation is the phosphorylation of the N-terminal domain of p53 by protein kinases, thereby transducing upstream stress signals. Phosphorylation of p53 leads to conformational changes that can promote DNA binding by p53 and allow transcription of downstream effectors. Activation of p53 can induce, for example, intrinsic apoptosis pathways, extrinsic apoptosis pathways, cell cycle arrest, aging, and DNA repair. p53 can activate proteins involved in the above pathways, including, for example, Fas / Apo1, KILLER / DR5, Bax, Puma, Noxa, Bid, caspase-3, caspase-6, caspase-7, caspase-8, caspase-9, and p21 (WAF1). In addition, p53 can repress the transcription of multiple genes including, for example, c-MYC, Cyclin B, VEGF, RAD51, and hTERT.
[0030] Each chain of the p53 tetramer consists of several functional domains, including the transactivation domain (amino acids 1-100), the DNA binding domain (amino acids 101-306) and the tetramerization domain (amino acids 307-355), which are highly mobile and essentially unstructured. Most p53 cancer mutations are located in the DNA binding core domain of the protein, which contains a central b-sandwich structure of antiparallel b-sheets that serves as the basic scaffold of the DNA binding surface. The DNA binding surface consists of two b-turn loops L2 and L3 stabilized by zinc ions, for example at Arg175 and Arg248, and a loop-sheet-helix motif. In summary, these structural elements form an extended DNA binding surface that is rich in positively charged amino acids and makes specific contacts with various p53 response elements.
[0031] Due to the prevalence of p53 mutations in almost every type of cancer, reactivating wild-type p53 function in cancerous cells can be an effective therapy. Mutations in p53 located in the DNA binding domain of the protein or in the periphery of the DNA binding surface lead to abnormal protein folding required for DNA recognition and binding. Mutations in p53 can occur, for example, at amino acids Val143, His168, Arg175, Tyr220, Gly245, Arg248, Arg249, Phe270, Arg273, and Arg282. P53 mutations that can eliminate the activity of p53 include, for example, R175H, Y220C, G245S, R248Q, R248W, R273H, and R282H. These p53 mutations can distort the structure of the DNA binding site or thermodynamically destabilize the folded protein at body temperature. The wild-type function of p53 mutants can be restored by binding the p53 mutants to compounds that shift the folding-unfolding equilibrium toward the folded state, thereby reducing the rate of unfolding and destabilization.
[0032] Non-limiting examples of amino acids include: alanine (A, Ala); arginine (R, Arg); asparagine (N, Asn); aspartic acid (D, Asp); cysteine (C, Cys); glutamic acid (E, Glu); glutamine (Q, Gln); glycine (G, Gly); histidine (H, His); isoleucine (I, Ile); leucine (L, Leu); lysine (K, Lys); methionine (M, Met); phenylalanine (F, Phe); proline (P, Pro); serine (S, Ser); threonine (T, Thr); tryptophan (W, Trp); tyrosine (Y, Tyr); and valine (V, Val).
[0033] Mechanism of the compounds of the present disclosure.
[0034] The compounds of the present disclosure can selectively bind to p53 mutants and can restore the wild-type activity of the p53 mutants, including, for example, DNA binding function and activation of downstream targets involved in tumor suppression. In some embodiments, the compounds of the present disclosure selectively bind to the p53 Y220C mutant. The Y220C mutant is a temperature-sensitive mutant that binds to DNA at lower temperatures and denatures at body temperature. The compounds of the present disclosure can stabilize the Y220C mutant to reduce the possibility of protein denaturation at body temperature.
[0035] Located in the periphery of the p53 b-sandwich structure connecting b-sheet strands S7 and S8, the aromatic ring of Y220 is an integral part of the hydrophobic core of the b-sandwich structure. The Y220C mutation can be highly destabilizing due to the formation of an inner surface cavity. The compounds of the present disclosure can bind to and occupy this surface cleft to stabilize the b-sandwich structure, thereby restoring wild-type p53 DNA binding activity.
[0036] To determine the ability of the disclosed compounds to bind and stabilize mutant p53, assays can be used to detect, for example, conformational changes of p53 mutants or activation of wild-type p53 targets. Conformational changes of p53 can be measured, for example, by differential scanning fluorimetry (DSF), isothermal titration calorimetry (ITC), nuclear magnetic resonance spectroscopy (NMR), or X-ray crystallography. In addition, antibodies specific for the wild-type of the mutant conformation of p53 can be used to detect conformational changes by, for example, immunoprecipitation (IP), immunofluorescence (IF), or immunoblotting.
[0037] Methods for detecting the ability of p53 mutants to bind DNA may include, for example, DNA affinity immunoblotting, modified enzyme-linked immunosorbent assay (ELISA), electrophoretic mobility shift assay (EMSA), fluorescence resonance energy transfer (FRET), homogeneous time-resolved fluorescence (HTRF), and chromatin immunoprecipitation (ChIP) assays.
[0038] To determine whether the compounds described herein can reactivate the transcriptional activity of p53, the activation of downstream targets in the p53 signaling cascade can be measured. The activation of p53 effector proteins can be detected by, for example, immunohistochemistry (IHC-P), reverse transcription polymerase chain reaction (RT-PCR), and western blotting. The activation of p53 can also be measured by the induction of apoptosis achieved via the caspase cascade and using methods including, for example, annexin V staining, TUNEL assays, procaspase and caspase levels, and cytochrome c levels. Another result of p53 activation is aging, which can be measured using methods such as b-galactosidase staining.
[0039] The p53 mutants that can be used to determine the effectiveness of the disclosed compounds in increasing the DNA binding ability of p53 mutants are p53 truncation mutants that contain only amino acids 94-312, encompassing the DNA binding domain of p53. For example, the sequence of the p53Y220C mutant used to test the efficacy of the compounds can be:
[0040]
[0041] The compounds of the present disclosure may increase the ability of a p53 mutant to bind DNA by at least or at most about 0.1%, at least or at most about 0.2%, at least or at most about 0.3%, at least or at most about 0.4%, at least or at most about 0.5%, at least or at most about 0.6%, at least or at most about 0.7%, at least or at most about 0.8%, at least or at most about 0.9%, at least or at most about 1%, at least or at most about 2%, at least or at most about 3%, at least or at most about 4%, at least or at most about 5%, at least or at most about 6%, at least or at most about 7%, at least or at most about 8%, at least or at most about 9%, at least or at most about 10%, at least %, at least or up to about 29%, at least or up to about 30%, at least or up to about 31%, at least or up to about 32%, at least or up to about 33%, at least or up to about 34%, at least or up to about 35%, at least or up to about 36%, at least or up to about 37%, at least or up to about 38%, at least or up to about 39%, at least or up to about 40%, at least or up to about 41%, at least or up to about 42%, at least or up to about 43%, at least or up to about 44%, at least or up to about 45%, at least or up to about 46%, at least or up to about 47%, at least or up to about 48%, at least or up to about 49%, at least or up to about 50%, at least or up to about 51%, at least or up to about 52%, at least or up to about 53%, at least or up to about 54%, at least or up to about 55%, at least or up to about 56%, at least or up to about 57%, at least or up to about 58%, at least or up to about 59%, at least or up to about 60%, at least or up to about 61%, at least or up to about at least or up to about 49%, at least or up to about 50%, at least or up to about 51%, at least or up to about 52%, at least or up to about 53%, at least or up to about 54%, at least or up to about 55%, at least or up to about 56%, at least or up to about 57%, at least or up to about 58%, at least or up to about 59%, at least or up to about 60%, at least or up to about 61%, at least or up to about 62%, at least or up to about 63%, at least or up to about 64%, at least or up to about 65%, at least or up to about 66%, at least or up to about 67%, at least or up to about 68%, at least or up to about 69%, at least or up to about 70%, at least or up to about 71%, at least or up to about 72%, at least or up to about 73%, at least or up to about 74%, at least or up to about 75%, at least or up to about 76%, at least or up to about 77%, at least or up to about 78%, at least or up to about 79%, at least or up to about 80%, At least or up to about 61%, at least or up to about 62%, at least or up to about 63%, at least or up to about 64%, at least or up to about 65%, at least or up to about 66%, at least or up to about 67%, at least or up to about 68%, at least or up to about 69%, at least or up to about 70%, at least or up to about 71%, at least or up to about 72%, at least or up to about 73%, at least or up to about 74%, at least or up to about 75%, at least or up to about 76%, at least or up to about 77%, at least or up to about 78%, at least or up to about 79%, at least or up to about 80%, at least or up to about 81%, at least or up to about 82%, at least or up to about 83%, at least or up to about 84%, at least or up to about 85%,At least or up to about 86%, at least or up to about 87%, at least or up to about 88%, at least or up to about 89%, at least or up to about 90%, at least or up to about 91%, at least or up to about 92%, at least or up to about 93%, at least or up to about 94%, at least or up to about 95%, at least or up to about 96%, at least or up to about 97%, at least or up to about 98%, at least or up to about 99%, at least or up to about 100%, at least or up to about 125%, at least or up to about 150%, at least or up to about 175%, at least or up to about 200%, at least or up to about 225%, or at least or up to about 250%.
[0042] The compounds described herein can increase the activity of a p53 mutant, e.g., by at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 11-fold, at least or up to about 12-fold, at least or up to about 13-fold, at least or up to about 14-fold, at least or up to about 15-fold, at least or up to about 16-fold, at least or up to about 17-fold, at least or up to about 18-fold, at least or up to about 19-fold, at least or up to about 20-fold, at least or up to about 21-fold, at least or up to about 22-fold, at least or up to about 23-fold, at least or up to about 24-fold, at least or up to about 25-fold, at least or up to about 26-fold, at least or up to about 27-fold, at least or up to about 18 times, at least or up to about 19 times, at least or up to about 20 times, at least or up to about 25 times, at least or up to about 30 times, at least or up to about 35 times, at least or up to about 40 times, at least or up to about 45 times, at least or up to about 50 times, at least or up to about 55 times, at least or up to about 60 times, at least or up to about 65 times, at least or up to about 70 times, at least or up to about 75 times, at least or up to about 80 times, at least or up to about 85 times, at least or up to about 90 times, at least or up to about 95 times, at least or up to about 100 times, at least or up to about 110 times, at least or up to about 120 times, at least or up to about 130 times, at least or up to about 140 times, at least or up to about 150 times, at least or up to about 160 times, at least or up to about 170 times, at least or up to about 180 times, at least or up to about 190 times, at least or up to about 200 times, at least or up to about 210 times, at least or up to about 211 times, at least or up to about 220 times, at least or up to about 230 times, at least or up to about 240 times, at least or up to about 250 times At least or up to about 120 times, at least or up to about 130 times, at least or up to about 140 times, at least or up to about 150 times, at least or up to about 160 times, at least or up to about 170 times, at least or up to about 180 times, at least or up to about 190 times, at least or up to about 200 times, at least or up to about 250 times, at least or up to about 300 times, at least or up to about 350 times, at least or up to about 400 times, at least or up to about 450 times, at least or up to about 500 times, at least or up to about 550 times, at least or up to about 600 times, at least or up to about 650 times, at least or up to about 700 times, at least or up to about 710 times, at least or up to about 720 times, at least or up to about 730 times, at least or up to about 740 times, at least or up to about 750 times, at least or up to about 760 times, at least or up to about 770 times, at least or up to about 780 times, at least or up to about 790 times, at least or up to about 800 times, at least or up to about 810 times, at least or up to about 820 times, at least or up to about 830 times, at least or up to about 840 times In some embodiments, the present invention may be at least or up to about 1,000 times, at least or up to about 750 times, at least or up to about 800 times, at least or up to about 850 times, at least or up to about 900 times, at least or up to about 950 times, at least or up to about 1,000 times, at least or up to about 1,500 times, at least or up to about 2,000 times, at least or up to about 3,000 times, at least or up to about 4,000 times, at least or up to about 5,000 times, at least or up to about 6,000 times, at least or up to about 7,000 times, at least or up to about 8,000 times, at least or up to about 9,000 times, or at least or up to about 10,000 times.
[0043] The compounds of the present disclosure can be used, for example, to induce apoptosis, cell cycle arrest, or senescence of cells. In some embodiments, the cells are cancer cells. In some embodiments, the cells carry a mutation in p53.
[0044] Compounds of the present disclosure.
[0045] In some embodiments, the compound includes one or more isotopically enriched atoms. For example, compounds within the scope of the present disclosure have hydrogen atoms substituted with deuterium or a deuterated group [D].
[0046] Isotopically-labeled compounds of the present disclosure can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples and preparations, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously used.
[0047] In some embodiments, the present disclosure provides a composition comprising a population of molecules, wherein the population of molecules has a mass of at least 1 μg, wherein at least 10% of the molecules in the population of molecules each independently comprise a deuterium atom, wherein each molecule is a compound of the formula:
[0048]
[0049] in:
[0050] - Each are independently a single bond or a double bond;
[0051] -X 1 Yes CR 5 , CR 5 R 6 , N, NR 5 , O, S, C=O, C=S or connected to Q 1 of carbon atoms;
[0052] -X 2 Yes CR 7 , CR 7 R 8 , N, NR 7 , O, S, C=O, C=S or connected to Q 1 of carbon atoms;
[0053] -X 3 Yes CR 9 , CR 9 R 10 , N, NR 9 , O, S, C=O, C=S or connected to Q 1 of carbon atoms;
[0054] -X 4 Yes CR 11 , CR 11 R 12 , N, NR 11 , O, S, C=O, C=S or connected to Q 1 of carbon atoms;
[0055] -X5 Yes CR 13 , N or NR 13 ;
[0056] Where X 1 , X 2 , X 3 and X 4 At least one of them is connected to Q 1 of carbon atoms;
[0057] -Q 1 is alkylene, alkenylene or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, C=CR 14 R 15 、C=NR 14 or key;
[0058] -m is 1, 2, 3, or 4;
[0059] -Y is N;
[0060] -R 1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl, each of which is independently substituted or unsubstituted, or -C(O)R 16 、-C(O)OR 16 、-C(O)NR 16 R 17 ,
[0061] -OR 16 、-SR 16 、-NR 16 R 17 、-NR 16 C(O)R 16 、-OC(O)R 16 、-CN、-SiR 16 R 17 R 18 or hydrogen;
[0062] - Each R 3 and R 4 is independently alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl or heterocyclyl, each of which is independently substituted or unsubstituted, or -C(O)R 19 、-C(O)OR 19 、-C(O)NR 19 R 20 、-SOR 19 、-SO2R 19 or hydrogen, or R 3 and R 4 With R 3 and R 4The bound nitrogen atoms together form a ring, wherein the ring is substituted or unsubstituted;
[0063] - Each R 2 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and R 18 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl, each of which is independently substituted or unsubstituted, or -C(O)R 21 、-C(O)OR 21 ,
[0064] -C(O)NR 21 R 22 、-OR 21 、-SR 21 、-NR 21 R 22 、-NR 21 C(O)R 22 、-OC(O)R 21 , hydrogen or halogen;
[0065] - Each R 19 and R 20 is alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl, each of which is independently substituted or unsubstituted, or C(O)R 23 、-C(O)OR 23 、-
[0066] C(O)NR 23 R 24 、-OR 23 、-SR 23 、-NR 23 R 24 、-NR 23 C(O)R 24 、-OC(O)R 23 , hydrogen or halogen;
[0067] - Each R 21 and R 22 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
[0068] - Each R 23 and R 24 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or a pharmaceutically acceptable salt thereof,
[0069] wherein said compound is optionally substituted with at least one deuterated [D] group.
[0070] In some embodiments, Q 1 is a bond. In some embodiments, Q 1 In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.
[0071] In some embodiments, the pattern of dashed bonds is selected to provide an aromatic system, such as indole, indolene, pyrrolopyridine, pyrrolopyrimidine, or pyrrolopyrazine.
[0072] In some embodiments, X 1 Yes CR 5 , CR 5 R 6 Or connect to Q 1 In some embodiments, X 2 Yes CR 7 , CR 7 R 8 Or connect to Q 1 In some embodiments, X 3 Yes CR 9 , CR 9 R 10 Or connect to Q 1 In some embodiments, X 4 Yes CR 11 , CR 11 R 12 Or connect to Q 1 In some embodiments, X 5 Yes CR 13 , N or NR 13 In some embodiments, X 1 is connected to Q 1 In some embodiments, X 2 is connected to Q 1 In some embodiments, X 3 is connected to Q 1 In some embodiments, X 4 is connected to Q 1 In some embodiments, X5 It is N.
[0073] In some embodiments, the present disclosure provides a composition comprising a population of molecules, wherein the population of molecules has a mass of at least 1 μg, wherein at least 10% of the molecules in the population of molecules each independently comprise a deuterium atom, wherein each molecule is a compound of formula (I'):
[0074]
[0075] in:
[0076] -R 1 selected from aryl, heteroaryl and heterocyclic groups, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the group consisting of hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic group, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R 21 and ester groups;
[0077] R 2 is an alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclic group, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the group consisting of a hydroxyl group, a thiol group, a halogen group, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group, -P(O)R 21 and an ester group; or
[0078] Hydrogen, -C(O)R 21 、-C(O)OR 21 、-C(O)NR 21 R 22 、-OR 21 、-SR 21 、-NR 21 R 22 ,
[0079] -NR 21 C(O)R 22 or -OC(O)R 21 ;
[0080] -R 3 It is H;
[0081] -R 4 is a heterocyclic group substituted by one, two or three substituents selected from the group consisting of a halogen group, a hydroxyl group, a sulfhydryl group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group, -P(O)R 21 and
[0082] Ester group;
[0083] - Each R 21 and R 22 is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclic, each of which is independently substituted or unsubstituted,
[0084] or a pharmaceutically acceptable salt thereof,
[0085] wherein said compound is optionally substituted with at least one deuterium atom.
[0086] In some embodiments, the present disclosure provides a composition comprising a population of molecules, wherein the population of molecules has a mass of at least 1 μg, wherein at least 10% of the molecules in the population of molecules each independently comprise a deuterium atom, wherein each molecule is a compound of formula (I):
[0087]
[0088] in:
[0089] -R 1 selected from aryl, heteroaryl and heterocyclic groups, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the group consisting of hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic group, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R 21 and ester groups;
[0090] -R 2 is an alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl group, each of which is independently unsubstituted or substituted with one, two or three substituents selected from the following:
[0091] hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R 21 and ester groups; or hydrogen groups, -C(O)R 21 、-C(O)OR 21 、-C(O)NR 21 R 22 、-OR 21 ,
[0092] -SR 21 、-NR 21 R 22 、-NR 21 C(O)R 22 or -OC(O)R 21 ;
[0093] -R 3 It is H;
[0094] -R 4 is a heterocyclic group substituted by one, two or three substituents selected from the group consisting of a halogen group, a hydroxyl group, a sulfhydryl group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group,
[0095] -P(O)R 21 and an ester group; and
[0096] - Each R 21 and R 22 is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclic, each of which is independently substituted or unsubstituted,
[0097] or a pharmaceutically acceptable salt thereof,
[0098] wherein said compound is optionally substituted with at least one deuterated [D] group.
[0099] In some embodiments, R 1 is an aryl group independently substituted with one, two or three substituents selected from the group consisting of alkylsulfonyl, alkoxy, alkylaminocarbonyl, deuterated alkoxy and (deuterated alkyl)aminocarbonyl.
[0100] In some embodiments, R 1 is phenyl substituted independently by one, two or three substituents selected from the group consisting of: C 1-4 Alkylsulfonyl, C 1-4 Alkoxy, C 1-4 Alkylaminocarbonyl, deuterated C 1-4 Alkoxy and (deuterated C 1-4 alkyl)aminocarbonyl.
[0101] In some embodiments, R 1 is phenyl substituted independently with one, two or three substituents selected from the group consisting of methylsulfonyl, methoxy, methylaminocarbonyl, trideuteromethoxy and (trideuteromethyl)aminocarbonyl.
[0102] In some embodiments, R 2 It is an alkyl group which is unsubstituted or substituted by a halogen group.
[0103] In some embodiments, R 2 It is C 1-4 Halogenated alkyl.
[0104] In some embodiments, R 2 It is 1,1,1-trifluoroethyl.
[0105] In some embodiments, R 4 is 4-piperidinyl which is unsubstituted or substituted by one, two or three substituents selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 Alkoxy-(hydroxy)-C 1-4 alkyl.
[0106] In some embodiments, R 4 is 4-piperidinyl substituted by fluoro and one or two further substituents selected from the group consisting of methyl, trideuteromethyl, tert-butyl, 2-hydroxy-methoxypropyl and 2-hydroxy-trideuteromethoxypropyl.
[0107] In some embodiments, the present disclosure provides a composition comprising a population of molecules, wherein the population of molecules has a mass of at least 1 μg, wherein each molecule is a compound of formula (II):
[0108]
[0109] in:
[0110] -R 2 is a C1-C4 haloalkyl group,
[0111] -R 25is selected from hydrogen, hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, alkylsulfonyl, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, deuterated alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic, acyl, acyloxy, carbamate, amide, deuterated alkylamide, urea, epoxy, -P(O)R 21 and ester groups;
[0112] -R 26 is selected from the group consisting of hydrogen, hydroxy, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, deuterated alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic, acyl, acyloxy, carbamate, amide, deuterated amide, urea, epoxy, -P(O)R 21 and ester groups;
[0113] -R 27 selected from the group consisting of hydrogen groups substituted by hydroxyl groups, sulfhydryl groups, halogen groups, amino groups, nitro groups, nitroso groups, cyano groups, azido groups, sulfoxide groups, sulfone groups, sulfonamide groups, carboxyl groups, carboxaldehyde groups, imine groups, alkyl groups, haloalkyl groups, alkenyl groups, haloalkenyl groups, alkynyl groups, haloalkynyl groups, alkoxy groups, aryl groups, aryloxy groups, aralkyl groups, arylalkoxy groups, heterocyclic groups, acyl groups, acyloxy groups, carbamate groups, amide groups, urea groups, epoxy groups, -P(O)R 21 and an ester group; and
[0114] -R 28 is selected from hydrogen, hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, deuterated alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R 21 and ester groups,
[0115] or a pharmaceutically acceptable salt thereof;
[0116] Provided that in at least 10% of said population of molecules, R 25 , R 26 , R 27 or R 28 One or more of independently comprises a deuterated group.
[0117] In some embodiments, R 2 is 1,1,1-trifluoroethyl; R 25 is selected from C1-C4 alkylaminocarbonyl, deuterated C1-C4 alkylaminocarbonyl or C1-C4 alkylsulfonyl; R 26 is C1-C4 alkoxy or deuterated C1-C4 alkoxy; R 27 is a hydrogen group or a fluoro group; and R 28 It is selected from C1-C4 alkyl, deuterated C1-C4 alkyl, C1-C4 alkoxy-C1-C4 alkyl optionally substituted with hydroxyl, or deuterated C1-C4 alkoxy-C1-C4 alkyl optionally substituted with hydroxyl.
[0118] In some embodiments, R 25 is methylsulfonyl, methylaminocarbonyl or trideuterated methylaminocarbonyl; R 26 is methoxy or trideuterated methoxy; and R 28 It is selected from methyl, tert-butyl, deuterated methyl, 2-hydroxy-1-methoxypropyl or 1-trideuterated methoxy-2-hydroxypropyl.
[0119] Non-limiting examples of compounds of the present disclosure include the following:
[0120]
[0121]
[0122] Non-limiting examples of compounds of the present disclosure include the following:
[0123]
[0124]
[0125] The compounds herein may include all stereoisomers, enantiomers, diastereomers, mixtures, racemates, atropisomers and tautomers thereof.
[0126] In some cases, the deuterated compounds of the present disclosure provide a plasma AUC of 0-24 , which is greater than the plasma AUC of similar compounds in primates 0-24 , wherein the analogous compound is identical to the deuterated compound, except that the analogous compound has a hydrogen atom instead of a deuterium atom. In some embodiments, the analogous compound is Compound C:
[0127]
[0128] In some cases, the deuterated compound has improved exposure relative to the exposure exhibited by a similar compound. In some embodiments, the AUC of the deuterated compound is0-24 Compared with the AUC observed for similar compounds 0-24 About 10%, about 20%, about 30%, about 40%, about 50%, about 60% or about 70%.
[0129] Deuterated compounds of the present disclosure can be glucuronidated in primates at a rate that is less than the glucuronidation rate of a similar compound in a primate, wherein the similar compound is identical to the deuterated compound except that the similar compound has a hydrogen atom instead of a deuterium atom. In some cases, the rate of glucuronidation of the deuterated compound in a primate is about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, or about 70% of the glucuronidation rate of the similar compound in a primate.
[0130] Non-limiting examples of optional substituents include hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R A and an ester group, wherein R A is a hydrogen group, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group or a heterocyclic group.
[0131] Non-limiting examples of alkyl and alkylene groups include straight chain, branched chain, and cyclic alkyl and alkylene groups. The alkyl or alkylene group may be, for example, C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 or C 50 A non-limiting example of an alkyl group may be C 1-4 -alkyl.
[0132] Non-limiting examples of straight chain alkyl include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl. Branched chain alkyl includes any straight chain alkyl substituted by any number of alkyl. Non-limiting examples of branched chain alkyl include isopropyl, isobutyl, sec-butyl and tert-butyl. Non-limiting examples of substituted alkyl include hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1-chloroethyl, 2-hydroxyethyl, 1,2-difluoroethyl and 3-carboxylpropyl. Non-limiting examples of cyclic alkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Cyclic alkyl also includes fused, bridged and spiral-connected bicyclic and higher fused, bridged and spiral-connected systems. Cyclic alkyl can be substituted by any number of straight chain, branched or cyclic alkyl. Non-limiting examples of cyclic alkyl groups include cyclopropyl, 2-methyl-cycloprop-1-yl, cycloprop-2-en-1-yl, cyclobutyl, 2,3-dihydroxycyclobut-1-yl, cyclobut-2-en-1-yl, cyclopentyl, cyclopent-2-en-1-yl, cyclopent-2,4-dien-1-yl, cyclohexyl, cyclohex-2-en-1-yl, cycloheptyl, cyclooctyl, 2,5-dimethylcyclopent-1-yl, 3,5-dichlorocyclohex-1-yl, 4-hydroxycyclohex-1-yl, cyclopentyl, cyclopent-2-en-1-yl, cyclopent ...yl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, cyclopentyl, 1-yl, 3,3,5-trimethylcyclohex-1-yl, octahydropentalenyl, octahydro-1H-indenyl, 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl, decahydroazulenyl, bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl and bicyclo[3.3.3]undecyl.
[0133] Non-limiting examples of deuterated alkyl groups include monodeuterated, dideuterated, trideuterated to perdeuterated alkyl groups.
[0134] Non-limiting examples of alkenyl and alkenylene groups include straight chain, branched chain, and cyclic alkenyl groups. The one or more alkenyl groups of the alkenyl group may be in the form of, for example, E, Z, cis, trans, terminal, or exo-methylene. The alkenyl or alkenylene group may be, for example, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 or C 50 A group, which is substituted or unsubstituted. Non-limiting examples of alkenyl and alkenylene include vinyl, prop-1-ene-1-yl, isopropenyl, but-1-ene-4-yl; 2-chlorovinyl, 4-hydroxybutene-1-yl, 7-hydroxy-7-methyloct-4-ene-2-yl and 7-hydroxy-7-methyloct-3,5-diene-2-yl.
[0135] Non-limiting examples of alkynyl or alkynylene groups include straight chain, branched chain, and cyclic alkynyl groups. The triple bond of the alkynyl or alkynylene group may be internal or at a terminal end. The alkynyl or alkynylene group may be, for example, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , C 12 , C 13 , C14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 or C 50 Group, described group is substituted or unsubstituted.The limiting examples of alkynyl or alkynylene include ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl and 2-methyl-hex-4-yn-1-yl; 5-hydroxy-5-methyl hex-3-yn-1-yl, 6-hydroxy-6-methyl hept-3-yn-2-yl and 5-hydroxy-5-ethyl hept-3-yn-1-yl.
[0136] The haloalkyl group may be any alkyl group substituted with any number of halogen atoms such as fluorine, chlorine, bromine and iodine atoms. Non-limiting examples of haloalkyl groups may be C 1-4 -haloalkyl. A haloalkenyl group may be any alkenyl group substituted by any number of halogen atoms. A haloalkynyl group may be any alkynyl group substituted by any number of halogen atoms.
[0137] Alkoxy may be, for example, an oxygen atom substituted by any alkyl, alkenyl or alkynyl group. Non-limiting examples of alkoxy may be C 1-4 -alkoxy. Ether or ether group comprises alkoxy. Non-limiting examples of alkoxy include methoxy, ethoxy, propoxy, isopropoxy and isobutoxy. Non-limiting examples of deuterated alkyl include monodeuterated, dideuterated, trideuterated to perdeuterated alkyl.
[0138] The alkylsulfonyl group may be, for example, a sulfonyl group [-SO2-] substituted by any alkyl group. Non-limiting examples of the alkylsulfonyl group may be C 1-4 Alkylsulfonyl, for example methylsulfonyl.
[0139] The alkylaminocarbonyl group may be, for example, an aminocarbonyl group {-NHCO2-] substituted by any alkyl group. Non-limiting examples of the alkylaminocarbonyl group may be C 1-4 Alkylaminocarbonyl, for example methylaminocarbonyl.
[0140] The aryl group may be heterocyclic or non-heterocyclic. The aryl group may be monocyclic or polycyclic. The aryl group may be substituted by any number of substituents described herein, such as hydrocarbyl, alkyl, alkoxy and halogen atoms. Non-limiting examples of aryl groups include phenyl, toluoyl, naphthyl, pyrrolyl, pyridyl, imidazolyl, thienyl and furyl. Non-limiting examples of substituted aryl groups include 3,4-dimethylphenyl, 4-tert-butylphenyl, 4-cyclopropylphenyl, 4-diethylaminophenyl, 4-(trifluoromethyl)phenyl, 4-(difluoromethoxy)-phenyl, 4-(trifluoromethoxy)phenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 2-chlorophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-methylphenyl, 3-fluorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-methylphenyl, 4-methoxyphenyl, 2, 3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,4,5-trifluorophenyl, 2,4,6-trifluorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trichlorophenyl, 2,4,5-trichlorophenyl, 3,4,5-trichlorophenyl, 2,4,6-trichlorophenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethylphenyl, 2 ,3,6-trimethylphenyl, 2,4,5-trimethylphenyl, 2,4,6-trimethylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2,3-diethylphenyl, 2,4-diethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethylphenyl, 2,3,4-triethylphenyl, 2,3,5-triethylphenyl, 2,3,6-triethylphenyl, 2,4,5-triethylphenyl, 2,4,6-triethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl and 4-isopropylphenyl.Non-limiting examples of substituted aryl groups include 2-aminophenyl, 2-(N-methylamino)phenyl, 2-(N,N-dimethylamino)phenyl, 2-(N-ethylamino)phenyl, 2-(N,N-diethylamino)phenyl, 3-aminophenyl, 3-(N-methylamino)phenyl, 3-(N,N-dimethylamino)phenyl, 3-(N-ethylamino)phenyl, 3-(N,N-diethylamino)phenyl, 4-aminophenyl, 4-(N-methylamino)phenyl, 4-(N,N-dimethylamino)phenyl, 4-(N-ethylamino)phenyl, and 4-(N,N-diethylamino)phenyl.
[0141] Heterocycle can be any ring containing ring atoms such as N, O, S, P, Si, B or any other heteroatom that is not carbon.Heterocycle can be substituted by any number of substituents such as alkyl and halogen atoms.Heterocycle can be aromatic (heteroaryl) or non-aromatic.Non-limiting examples of heterocycle include pyrrole, pyrrolidine, pyridine, piperidine, succinimide, maleimide, morpholine, imidazole, thiophene, furan, tetrahydrofuran, pyran and tetrahydropyran.
[0142] Non-limiting examples of heterocycles include heterocyclic units having a single ring containing one or more heteroatoms, non-limiting examples of which include diazolidinyl, aziridinyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolinyl, oxathiazolidinone, oxazolidinone, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidin-2-one, 2,3,4,5-tetrahydro- 1H-azepine, 2,3-dihydro-1H-indole and 1,2,3,4-tetrahydroquinoline; and ii) a heterocyclic unit having 2 or more rings, one of which is a heterocycle, non-limiting examples of which include hexahydro-1H-pyrrolazinyl, 3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazolyl, 3a,4,5,6,7,7a-hexahydro-1H-indolyl, 1,2,3,4-tetrahydroquinolinyl and decahydro-1H-cyclooctatetraen[b]pyrrolyl.
[0143] Non-limiting examples of heteroaryl groups include: i) heteroaryl rings containing a single ring, non-limiting examples of which include 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazolyl, 1H-imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, thienyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl; and ii) heteroaryl rings containing 2 or more Non-limiting examples of multiple fused rings, one of which is a heteroaryl ring, include 7H-purinyl, 9H-purinyl, 6-amino-9H-purinyl, 5H-pyrrolo[3,2-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 4,5,6,7-tetrahydro-1-H-indolyl, quinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxy-quinolinyl, and isoquinolinyl.
[0144] Any of the compounds herein may be purified. The compounds herein may be at least 1% pure, at least 2% pure, at least 3% pure, at least 4% pure, at least 5% pure, at least 6% pure, at least 7% pure, at least 8% pure, at least 9% pure, at least 10% pure, at least 11% pure, at least 12% pure, at least 13% pure, at least 14% pure, at least 15% pure, at least 16% pure, at least 17% pure, at least 18% pure, at least 19% pure, at least 20% pure, at least 21% pure, at least 22% pure, at least 23% pure, at least 24% pure, at least 25% pure, at least 26% pure, at least 27% pure, at least 28% pure, at least 29% pure, at least 30% pure, at least 31% pure, at least 32% pure, at least 33% pure, at least 34% pure, at least 35% pure, at least 36% pure, at least 37% pure, at least 38% pure, at least 39% pure, at least 40% pure, at least 41% pure, at least 42% pure, at least 43% pure, at least 44% pure, at least 45% pure, at least 46% pure, at least 47% pure, at least 48% pure, at least 49% pure, at least 50% pure, at least 51% pure, at least 52% pure, at least 53% pure, at least 54% pure, at least 55% pure, at least 56% pure, at least 57% pure, at least 58% pure, % pure, at least 29% pure, at least 30% pure, at least 31% pure, at least 32% pure, at least 33% pure, at least 34% pure, at least 35% pure, at least 36% pure, at least 37% pure, at least 38% pure, at least 39% pure, at least 40% pure, at least 41% pure, at least 42% pure, at least 43% pure, at least 44% pure, at least 45% pure, at least 46% pure, at least 47% pure, at least 48% pure, at least 49% pure, at least 50% pure, at least 51% pure, at least 52% pure, at least 53% pure, at least 54% pure, at least 55% pure, at least 56% pure, at least 57% pure, at least 58% pure, at least 59% pure, at least 60% pure, at least 61% pure, at least 62% pure, at least 63% pure, at least 64% pure, at least 65% pure, at least 66% pure, at least 67% pure, at least 68% pure, at least 69% pure At least 56% pure, at least 57% pure, at least 58% pure, at least 59% pure, at least 60% pure, at least 61% pure, at least 62% pure, at least 63% pure, at least 64% pure, at least 65% pure, at least 66% pure, at least 67% pure, at least 68% pure, at least 69% pure, at least 70% pure, at least 71% pure, at least 72% pure, at least 73% pure, at least 74% pure, at least 75% pure, at least 76% pure, at least 77% pure, at least 78% pure, at least 79% pure, at least 80% pure, at least 81% pure, at least 82% pure, at least 83% pure. In some embodiments, the present invention relates to a pure or at least 84% pure, at least 85% pure, at least 86% pure, at least 87% pure, at least 88% pure, at least 89% pure, at least 90% pure, at least 91% pure, at least 92% pure, at least 93% pure, at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, at least 99.1% pure, at least 99.2% pure, at least 99.3% pure, at least 99.4% pure, at least 99.5% pure, at least 99.6% pure, at least 99.7% pure, at least 99.8% pure, or at least 99.9% pure.
[0145] In some embodiments, disclosed herein is a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present disclosure. The compounds of the present disclosure can, for example, slow the proliferation of cancer cell lines, or kill cancer cells.Non-limiting examples of cancers that may be treated by the compounds of the present disclosure include acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphomas, anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain tumors (such as cerebellar astrocytoma, cerebral astrocytoma / glioblastoma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, optic pathway and hypothalamic gliomas), breast cancer, bronchial adenoma, Burkitt lymphoma, carcinoma of unknown origin, central nervous system lymphoma, cerebellar astrocytoma, cervical cancer, childhood cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, colon cancer, cutaneous T-cell lymphoma, desmoplastic small round cell tumor, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, sarcoma), germ cell tumors, gallbladder cancer, stomach cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, gliomas, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular (liver) cancer, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell carcinoma, Kaposi sarcoma, kidney cancer, laryngeal cancer, lip and oral cancer, liposarcoma, liver cancer, lung cancer (such as non-small cell lung cancer and small cell lung cancer), lymphoma, leukemia, macroglobulinemia, malignant bone fibrous histiocytoma / osteosarcoma, medulloblastoma, melanoma, mesothelioma, metastatic squamous neck cancer with occult primary, oral cancer, multiple endocrine neoplasia syndrome, myelodysplastic syndrome, myeloid leukemia, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma / malignant bone fibrous histiocytoma, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, pancreatic cancer, islet cell pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal astrocytoma, pineal germ cell tumor, pituitary adenoma, pleuropulmonary blastoma, plasmacytoma formation, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, transitional cell carcinoma of the renal pelvis and ureter, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, skin cancer, merkel cell skin cancer (skincarcinoma merkel cell), small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, T-cell lymphoma, pharyngeal cancer, thymoma, thymic cancer, thyroid cancer, trophoblastic tumor (gestational), cancer of unknown primary site, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia (. macroglobulinemia and Wilms tumor.
[0146] In some embodiments, compounds of the present disclosure exhibit non-lethal toxicity.
[0147] In some embodiments, disclosed herein is a method for treating cancer, the method comprising administering a pharmaceutical composition of the present disclosure to a subject in need thereof. In some embodiments, the pharmaceutical composition comprises a population of molecules, wherein the population of molecules has a mass of at least 1 μg, wherein at least 10% of the molecules in the population of molecules each independently comprise a deuterium atom, wherein each molecule is a compound of formula (I):
[0148]
[0149] in:
[0150] -R 1 selected from aryl, heteroaryl and heterocyclic groups, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the group consisting of hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic group, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R 21 and ester groups;
[0151] -R 2 is an alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl group, each of which is independently unsubstituted or substituted with one, two or three substituents selected from the following:
[0152] A hydroxyl group, a sulfhydryl group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group, and an ester group;
[0153] or hydrogen, -C(O)R 21 、-C(O)OR 21 、-C(O)NR 21 R 22 、-OR 21 、-SR 21 、-NR 21 R 22 ,
[0154] -NR 21 C(O)R 22or -OC(O)R 21 ;
[0155] -R 3 It is H;
[0156] -R 4 is a heterocyclic group substituted by one, two or three substituents selected from the group consisting of a halogen group, a hydroxyl group, a sulfhydryl group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group and an ester group; and
[0157] - Each R 21 and R 22 is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl, each of which is independently substituted or unsubstituted;
[0158] or a pharmaceutically acceptable salt thereof,
[0159] wherein the compound is optionally substituted with at least one deuterium atom and the compound has a SC of less than 1 mM for p53 Y220C 150 Values, as measured by homogeneous time-resolved fluorescence (HTRF) assay.
[0160] In some embodiments, disclosed herein is a method of inducing apoptosis, the method comprising contacting the cell with a therapeutically effective amount of a pharmaceutical composition disclosed herein. In some embodiments, disclosed herein is a method of inducing apoptosis, the method comprising contacting the cell with a therapeutically effective amount of a compound that binds to a p53 mutant, wherein the compound is a compound disclosed herein. In some embodiments, the compound increases the ability of the p53 mutant to bind to DNA. In some embodiments, the cell expresses the p53. In some embodiments, the p53 mutant has a mutation at amino acid 220. In some embodiments, the p53 mutant is p53 Y220C. In some embodiments, the compound induces conformational changes in the p53 mutant. In some embodiments, the compound selectively binds to the p53 mutant compared to wild-type p53. In some embodiments, the therapeutically effective amount is about 50 mg to about 3000 mg. In some embodiments, relative to the stability of the biologically active conformation of the p53 mutant in the absence of the compound, the compound increases the stability of the biologically active conformation of the p53 mutant.
[0161] Unless otherwise stated, when a position in a specific or general formula of the present disclosure (e.g., Compound 1 or Formula (I)) is implicitly or explicitly designated as "H" or "hydrogen", in a composition containing a plurality of molecules, each of which is independently a compound according to the formula, the proportion of the plurality of molecules having hydrogen at that position is equal to the natural isotopic abundance of hydrogen at that position. However, in some embodiments, where specifically stated, when a position is specifically designated as "H" or "hydrogen", the proportion of the plurality of molecules having deuterium at that position is <5 mol%, <4 mol%, <3 mol%, <2 mol%, or <1 mol%.
[0162] In some embodiments, when a position in a specific or general formula of the present disclosure (e.g., Compound 1 or Formula (I)) is designated as "D" or "deuterium," in a composition comprising a plurality of molecules, each molecule independently being a compound according to that formula, the proportion of the plurality of compounds having deuterium at that position is at least 3000 times the natural abundance of deuterium (i.e., at least 45 mol%), at least 3500 times the natural abundance of deuterium (i.e., at least 52.5 mol%), at least 4500 times the natural abundance of deuterium (i.e., at least 67.5 mol%), at least 5000 times the natural abundance of deuterium (i.e., at least 75 mol%), at least 50 ... ), at least 5000 (at least 75 mol%), at least 5500 times the natural abundance of deuterium (at least 82.5 mol%), at least 6000 times the natural abundance of deuterium (at least 90 mol%), at least 6333.3 times the natural abundance of deuterium (at least 95 mol%), at least 6466.7 times the natural abundance of deuterium (at least 97 mol%), at least 6600 times the natural abundance of deuterium (at least 99 mol%), or at least 6633.3 times the natural abundance of deuterium (at least 99.5 mol%).
[0163] In some embodiments, when a position in a specific or general formula of the present disclosure (e.g., Compound 1 or Formula (I)) is designated as "D" or "deuterium," in a composition containing a plurality of molecules, each of which is independently a compound according to that formula, the proportion of the plurality of molecules having deuterium at that position is at least about 10 mol%, at least about 25 mol%, at least about 50 mol%, at least about 75 mol%, at least about 80 mol%, at least about 82.5 mol%, at least about 85 mol%, at least about 87.5 mol%, at least about 90 mol%, at least about 92.5 mol%, at least about 95 mol%, at least about 96 mol%, at least about 97 mol%, at least about 98 mol%, at least about 99 mol%, or at least about 99.5 mol%.
[0164] The term "isotopic enrichment factor" at a particular position normally occupied by hydrogen means the ratio between the abundance of deuterium at that position and the natural abundance of hydrogen at that position. For example, an isotopic enrichment factor of 3500 means that the amount of deuterium at a particular position is 3500 times the natural abundance, or that 52.5% of the compounds have deuterium at the particular position (i.e., 52.5% of deuterium is incorporated into a given position).
[0165] When a particular position in a compound of the present disclosure is designated by name or structure as containing hydrogen or deuterium, it is understood that the position may contain hydrogen in its natural abundance, or may be enriched in deuterium with an isotopic enrichment factor, for example, of at least 835 (13% deuterium incorporation), at least 1670 (26% deuterium incorporation, at least 3500 (52.5% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
[0166] "Substitution with deuterium" means replacement of one or more hydrogen atoms by a corresponding number of deuterium atoms. Mass Spectrometry.
[0167] Different methods for obtaining mass spectrometer signals are known in the art. In various embodiments, mass spectrometry includes ionizing one or more compounds to generate charged molecules or molecular fragments and measuring their mass-to-charge ratio (see Sparkman, OD (2000). Mass spectrometry desk reference. Pittsburgh: Global View Pub. ISBN 0-9660813-2-3). Such procedures may include the following steps: loading a mixture containing one or more compounds onto an MS instrument and evaporating one or more compounds; ionizing the components of the mixture to form charged particles (ions); electromagnetically separating ions according to their mass-to-charge ratio in an analyzer; detecting ions (e.g., by quantitative methods); and converting ion signals into mass spectra.
[0168] The mass spectrometer can be operated, for example, in any of the following modes: (1) full scan, for example, the mass spectrometer detects all ions between two distant points on the m / z scale (such as 0 and 10000); (2) single ion monitoring (SIM) or single ion recording (SIR), for example, the mass spectrometer only detects ions having a specific m / z value or within a small m / z range (e.g., a range of 1 or 2 mass units); (3) multiple reaction monitoring (MRM), in a mass spectrometer having multiple mass spectrometer units, at least two units are operated in SIM / SIR mode.
[0169] After separation and measurement of the intensities of the ions in a mass spectrometer, a mass spectrum is created, for example, by plotting the intensities of the detected ions relative to their mass-to-charge ratio (m / z) measurements. Depending on the mode in which the mass spectrometer is operated (full scan, SIM / SIR, or MRM), a mass spectrum may include (1) peaks corresponding to all ions (precursor ions and product ions) detected between two distant points on the m / z scale in the mass spectrometer; (2) peaks corresponding to (a) all ions having a particular m / z value or lying within a very small mass m / z range, and optionally (b) all product ions derived from the ions specified in (a); or (3) only one or more selected product / daughter ions (MRM channels).
[0170] For example, when the mass spectrometer is operated in MRM mode, a single mass spectrum for a deuterated analog and a corresponding target analyte can be created. A single mass spectrum will contain a peak for each analog and, if present in the sample, a peak for the corresponding target analyte. Alternatively, multiple mass spectra can be created for each analog and each corresponding target analyte, wherein each of the multiple mass spectra represents only one analog or target analyte. Such a single mass spectrum or multiple mass spectra can be created for each analog and a corresponding target analyte (e.g., in a panel).
[0171] A mass spectrum is created using MRM channels, and where peak intensities are plotted over time (such as retention time if the mass spectrometer is coupled to an SPE, chromatography or electrophoresis device), is often described as a mass chromatogram. Thus, the term mass spectrum as used herein may also refer to a mass chromatogram (e.g., where the MS is operated in MRM mode).
[0172] Next, the MS signal intensity (or relative signal intensity) of the ions representing each target analyte and the corresponding analog is determined. The signal intensity of the ions in the mass spectrum (e.g., the intensity of the peaks corresponding to these ions) can be determined on the basis of peak height or peak area, for example, on the basis of peak area, such as by integrating the signal intensity of a particular ion with respect to time. The intensity of the ion signal in the mass spectrum / mass spectra can be normalized (e.g., 100%) to the strongest ion signal detected.
[0173] A mass spectrometer (and the mass spectrometer of any method of the present disclosure) can essentially be any instrument comprising an ionization source, an analyzer, and a detector suitable for producing a mass spectrum. A mass spectrometer can contain multiple mass spectrometer units (MSn, where n=2, 3, 4...) and / or can be coupled to other instruments, such as chromatographic or electrophoretic devices (e.g., separation systems, such as in LC / MS / MS).
[0174] A mass spectrometer can include ion sources such as an electrospray ionization ("ESI") ion source; an atmospheric pressure photoionization ("APPI") ion source; an atmospheric pressure chemical ionization ("APCI") ion source; a matrix-assisted laser desorption ionization ("MALDI") ion source; a laser desorption ionization ("LDI") ion source; an atmospheric pressure ionization ("API") ion source; a desorption ionization on silicon ("DIOS") ion source; an electron impact ("EI") ion source; a chemical ionization ("CI") ion source; a field ionization ("FI") ion source; a field desorption ("FD") ion source; an inductively coupled plasma ("ICP") ion source; a fast atom bombardment ("FAB") ion source; a liquid secondary ion mass spectrometry ("LSIMS") ion source; a desorption electrospray ionization ("DESI") ion source; a nickel-63 radioactive ion source; an atmospheric pressure matrix-assisted laser desorption ionization ion source; and a thermal spray ion source.
[0175] The mass spectrometer may include a mass analyzer, such as a quadrupole mass analyzer; a 2D or linear quadrupole mass analyzer; a Paul or 3D quadrupole mass analyzer; a 2D or linear quadrupole ion trap mass analyzer; a Paul or 3D quadrupole ion trap mass analyzer; a Penning trap mass analyzer; an ion trap mass analyzer; a sector magnetic field mass analyzer; an ion cyclotron resonance ("ICR") mass analyzer; a Fourier transform ion cyclotron resonance ("FTICR") mass analyzer; an electrostatic or orbital trap mass analyzer; a Fourier transform electrostatic or orbital trap mass analyzer; a Fourier transform mass analyzer; a time-of-flight mass analyzer; an orthogonal accelerated time-of-flight mass analyzer; and a linear accelerated time-of-flight mass analyzer. The mass spectrometer may include an ion mobility analyzer.
[0176] A mass spectrometer can include an ionization source such as an electrospray ionization ("ESI") ion source; an atmospheric pressure photoionization ("APPI") ion source; an atmospheric pressure chemical ionization ("APCI") ion source; a matrix-assisted laser desorption ionization ("MALDI") ion source; a laser desorption ionization ("LDI") ion source; an atmospheric pressure ionization ("API") ion source; a desorption ionization on silicon ("DIOS") ion source; an electron impact ("EI") ion source; a chemical ionization ("CI") ion source; a field ionization ("FI") ion source; a field desorption ("FD") ion source; an inductively coupled plasma ("ICP") ion source; a fast atom bombardment ("FAB") ion source; a liquid secondary ion mass spectrometry ("LSIMS") ion source; a desorption electrospray ionization ("DESI") ion source; a nickel-63 radioactive ion source; an atmospheric pressure matrix-assisted laser desorption ionization ion source; and a thermal spray ion source.
[0177] Pharmaceutically acceptable salts.
[0178] The present disclosure provides the use of pharmaceutically acceptable salts of any therapeutic compound described herein. Pharmaceutically acceptable salts include, for example, acid addition salts and base addition salts. The acid added to the compound to form the acid addition salt may be an organic acid or an inorganic acid. The base added to the compound to form the base addition salt may be an organic base or an inorganic base. In some embodiments, the pharmaceutically acceptable salt is a metal salt. In some embodiments, the pharmaceutically acceptable salt is an ammonium salt.
[0179] Metal salts can be produced by adding an inorganic base to the compounds of the present disclosure. The inorganic base consists of a metal cation paired with an alkaline counterion, such as hydroxide, carbonate, bicarbonate, or phosphate. The metal can be an alkali metal, alkaline earth metal, transition metal, or main group metal. In some embodiments, the metal is lithium, sodium, potassium, cesium, cerium, magnesium, manganese, iron, calcium, strontium, cobalt, titanium, aluminum, copper, cadmium, or zinc.
[0180] In some embodiments, the metal salt is a lithium salt, sodium salt, potassium salt, cesium salt, cerium salt, magnesium salt, manganese salt, iron salt, calcium salt, strontium salt, cobalt salt, titanium salt, aluminum salt, copper salt, cadmium salt, or zinc salt.
[0181] Ammonium salts can be produced by adding ammonia or an organic amine to the compounds of the present disclosure. In some embodiments, the organic amine is triethylamine, diisopropylamine, ethanolamine, diethanolamine, triethanolamine, morpholine, N-methylmorpholine, piperidine, N-methylpiperidine, N-ethylpiperidine, dibenzylamine, piperazine, pyridine, pyrazole, pipyrrazole, imidazole, pyrazine or piperazine.
[0182] In some embodiments, the ammonium salt is a triethylamine salt, a diisopropylamine salt, a ethanolamine salt, a diethanolamine salt, a triethanolamine salt, a morpholine salt, an N-methylmorpholine salt, a piperidine salt, an N-methylpiperidine salt, an N-ethylpiperidine salt, a dibenzylamine salt, a piperazine salt, a pyridine salt, a pyrazole salt, a pipyrrazole salt, an imidazole salt, a pyrazine salt, or a piperazine salt.
[0183] Acid addition salts can be produced by adding acid to the compounds of the present disclosure. In some embodiments, acid is organic. In some embodiments, acid is inorganic. In some embodiments, acid is hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, nitrous acid, sulfuric acid, sulfurous acid, phosphoric acid, isonicotinic acid, lactic acid, salicylic acid, tartaric acid, ascorbic acid, gentisic acid, gluconic acid, glucuronic acid, saccharic acid, formic acid, benzoic acid, glutamic acid, pantothenic acid, acetic acid, propionic acid, butyric acid, fumaric acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, oxalic acid or maleic acid. In some embodiments, the salt is hydrochloride, hydrobromide, hydroiodide, nitrate, nitrite, sulfate, sulfite, phosphate, isonicotinate, lactate, salicylate, tartrate, ascorbate, gentisate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, pantothenate, acetate, propionate, butyrate, fumarate, succinate, methanesulfonate (mesylate), ethanesulfonate, benzenesulfonate, p-toluenesulfonate, citrate, oxalate, or maleate.
[0184] Pharmaceutical composition.
[0185] The pharmaceutical composition of the present disclosure can be used, for example, before, during or after treating an object with, for example, another medicament. The object can be, for example, an older adult, an adult, a teenager, a prepubertal teenager, a child, a toddler, an infant, a newborn, and a non-human animal. In some embodiments, the object is a patient. The pharmaceutical composition of the present disclosure can be a combination of any drug compound described herein with other chemical components such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, and / or excipients. The pharmaceutical composition facilitates the administration of the compound to an organism. The pharmaceutical composition can be administered in a therapeutically effective amount in the form of a pharmaceutical composition by various forms and routes (including, for example, intravenous, subcutaneous, intramuscular, oral, parenteral, ocular, subcutaneous, transdermal, nasal, vaginal, and topical administration). The pharmaceutical composition can be administered in a local manner, for example, by injecting the compound directly into an organ, optionally in the form of a reservoir or sustained release formulation or implant. The pharmaceutical composition can be provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of a medium release formulation. Rapid release forms can provide immediate release. Extended release formulations may provide controlled release or sustained delayed release.
[0186] For oral administration, the pharmaceutical composition can be formulated by combining the active compound with a pharmaceutically acceptable carrier or excipient. Such carriers can be used to prepare liquids, gels, syrups, elixirs, slurries or suspensions for oral ingestion by a subject. Non-limiting examples of solvents used in oral soluble preparations may include water, ethanol, isopropanol, saline, physiological saline, DMSO, dimethylformamide, potassium phosphate buffer, phosphate buffered saline (PBS), sodium phosphate buffer, 4-2-hydroxyethyl-1-piperazineethanesulfonic acid buffer (HEPES), 3-(N-morpholino) propanesulfonic acid buffer (MOPS), piperazine-N, N¢-bis(2-ethanesulfonic acid) buffer (PIPES) and saline sodium citrate buffer (SSC). Non-limiting examples of co-solvents used in oral soluble preparations may include sucrose, urea, Cremaphor, DMSO and potassium phosphate buffer.
[0187] Pharmaceutical preparations can be formulated for intravenous administration. Pharmaceutical compositions can be in the form of sterile suspensions, solutions or emulsions in oily or aqueous vehicles suitable for parenteral injection, and can contain preparatons, such as suspending agents, stabilizers and / or dispersants. Pharmaceutical preparations for parenteral administration include aqueous solutions of active compounds in water-soluble form. Suspensions of active compounds can be prepared into oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate or triglycerides, or liposomes. Suspensions may also contain agents suitable for stabilizers or agents that increase the solubility of compounds to allow the preparation of highly concentrated solutions. Alternatively, the active ingredient may be in the form of a powder for reconstitution with a suitable vehicle, such as sterile pyrogen-free water, before use.
[0188] The active compound can be administered topically and can be formulated into a variety of topically administrable compositions such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams and ointments. Such pharmaceutical compositions may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
[0189] The compounds of the present disclosure may be topically applied to the skin or a body cavity of a subject, such as the oral cavity, vaginal cavity, bladder cavity, cranial cavity, spinal cavity, thoracic cavity, or pelvic cavity. The compounds of the present disclosure may be applied to accessible body cavities.
[0190] The compounds may also be formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories or retention enemas containing conventional suppository bases such as cocoa butter or other glycerides and synthetic polymers such as polyvinylpyrrolidone and PEG. In suppository forms of the compositions, a low melting wax such as a mixture of fatty acid glycerides optionally in combination with cocoa butter may be melted.
[0191] In practicing the treatment or use methods provided herein, a therapeutically effective amount of a compound described herein is administered in the form of a pharmaceutical composition to a subject suffering from a disease or condition to be treated. In some embodiments, the subject is a mammal, such as a human. The therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used, and other factors. The compound may be used alone or in combination with one or more therapeutic agents as a component of a mixture.
[0192] Pharmaceutical compositions can be formulated using one or more physiologically acceptable carriers that facilitate processing of the active compounds into pharmaceutically usable preparations, including excipients and adjuvants. Depending on the chosen route of administration, the formulation can be modified. Pharmaceutical compositions containing the compounds described herein can be manufactured, for example, by mixing, dissolving, emulsifying, encapsulating, embedding or compressing processes.
[0193] The pharmaceutical composition may include at least one pharmaceutically acceptable carrier, diluent or excipient and a compound described herein in the form of a free base or a pharmaceutically acceptable salt. The pharmaceutical composition may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
[0194] Methods for preparing compositions comprising compounds described herein include formulating the compounds with one or more inert pharmaceutically acceptable excipients or carriers to form solid, semisolid or liquid compositions. Solid compositions include, for example, powders, tablets, dispersible granules, capsules and cachets. Liquid compositions include, for example, solutions in which the compounds are dissolved, emulsions containing the compounds, or solutions containing liposomes, micelles or nanoparticles containing the compounds as disclosed herein. Semisolid compositions include, for example, gels, suspensions and creams. The compositions may be in the form of liquid solutions or suspensions; solid forms suitable for dissolution or suspension in a liquid prior to use; or emulsions. These compositions may also contain small amounts of non-toxic auxiliary substances, such as wetting agents or emulsifiers, pH buffers, and other pharmaceutically acceptable additives.
[0195] Non-limiting examples of dosage forms suitable for use in the present disclosure include liquids, powders, gels, nanosuspensions, nanoparticles, microgels, aqueous or oily suspensions, emulsions, and any combination thereof. Non-limiting examples of pharmaceutically acceptable excipients suitable for use in the present disclosure include binders, disintegrants, antiadherents, antistatic agents, surfactants, antioxidants, coating agents, colorants, plasticizers, preservatives, suspending agents, emulsifiers, antimicrobial agents, spheroidizers, and any combination thereof.
[0196] The compositions of the present disclosure may be, for example, immediate release forms or controlled release formulations. Immediate release formulations may be formulated to allow compounds to act quickly. Non-limiting examples of immediate release formulations include formulations that can be easily soluble. Controlled release formulations may be adjusted so that the release rate and release profile of the active agent can match the physiological and time treatment requirements, or alternatively, have been formulated to achieve a pharmaceutical formulation that releases the active agent at a programmed rate. Non-limiting examples of controlled release formulations include granules, delayed release granules, hydrogels (e.g., with synthetic or natural sources), other gelling agents (e.g., dietary fibers that form gels), matrix-based formulations (e.g., formulations containing polymeric materials with at least one active ingredient dispersed therein), particles, polymer mixtures, and particle clusters within the matrix. In some embodiments, controlled release formulations are delayed release forms. Delayed release forms may be formulated to delay the action of the compound for an extended period of time. Delayed release forms may be formulated to delay the release of one or more compounds of an effective dose, for example, for about 4, about 8, about 12, about 16, or about 24 hours. Controlled release formulations may be sustained release forms. Sustained release forms can be formulated to, for example, maintain the effect of the compound over an extended period of time. Sustained release forms can be formulated to provide an effective dose of any compound described herein (e.g., to provide a physiologically effective blood profile) within about 4, about 8, about 12, about 16, or about 24 hours. Non-limiting examples of pharmaceutically acceptable excipients can be found, for example, in: Remington: The Science and Practice of Pharmacy, 19th Edition (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition (Lippincott Williams & Wilkins 1999), each of which is incorporated herein by reference in its entirety.
[0197] Multiple therapeutic agents can be administered in any order or simultaneously. In some embodiments, the compounds of the present disclosure are combined with treatments performed with another therapeutic agent, before the treatment, or after the treatment. If at the same time, multiple therapeutic agents can be provided in a single combined form or in multiple forms, such as multiple separate pill forms. The agents can be packaged together or individually in a single package or in multiple packages. One or all of the therapeutic agents can be given in multiple doses. If not at the same time, the time selection between multiple doses can vary, up to about one month. The therapeutic agents described herein can be administered before, during, or after the occurrence of a disease or condition, and the time selection for administering a composition containing a therapeutic agent can vary. For example, a compound can be used as a prophylactic agent and can be continuously administered to an object with a condition or disease tendency to reduce the possibility of a disease or condition occurring. The composition can be administered to an object as quickly as possible during or after the onset of symptoms. The administration of the therapeutic agent can be started within 48 hours before the onset of symptoms, within 24 hours before the onset of symptoms, within 6 hours before the onset of symptoms, or within 3 hours of the onset of symptoms. Initial administration can be performed by any practical route, such as by any route described herein, using any formulation described herein.
[0198] The compound can be administered as soon as practicable after the onset of a disease or condition is detected or suspected, and for a period of time necessary to treat the disease, such as, for example, from about 1 month to about 3 months. In some embodiments, the length of time for which the compound can be administered can be about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 3 months, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 4 months, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 5 months, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 53 weeks, about 54 weeks, about 55 weeks, about 56 weeks, about 57 weeks, about 58 weeks, about 59 weeks, about 60 weeks, about 61 weeks, about 62 weeks, about 63 weeks, about 64 weeks, about 65 weeks The duration of treatment may vary for each subject.
[0199] The pharmaceutical compositions described herein may be in a unit dosage form suitable for single administration of an exact dose. In a unit dosage form, the preparation is divided into a unit dose containing an appropriate amount of one or more compounds. The unit dose may be in the form of a package containing a discrete amount of preparation. Non-limiting examples are packaged injectables, vials or ampoules. Aqueous suspension compositions may be packaged in a single dose non-reclosable container. Multiple dose reclosable containers may be used, for example, with or without a preservative in combination. Injectable preparations may be provided in a unit dosage form, for example, in an ampoule or in a multidose container with a preservative. The pharmaceutical compositions provided herein may be administered in combination with other therapies, such as chemotherapy, radiation, surgery, anti-inflammatory agents and selected vitamins. Other agents may be administered before, after or in conjunction with the pharmaceutical composition. Depending on the predetermined mode of administration, the pharmaceutical composition can be in the form of solid, semisolid or liquid dosage forms, such as tablets, suppositories, pills, capsules, powders, liquids, suspensions, lotions, creams or gels, for example, in a unit dosage form suitable for single administration of precise doses. For solid compositions, non-toxic solid carriers include, for example, pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose and magnesium carbonate. Non-limiting examples of pharmaceutically active agents suitable for use in combination with the compositions of the present disclosure include anti-infective agents, i.e. aminoglycosides, antiviral agents, antimicrobial agents, anticholinergic agents / spasmodics, antidiabetic agents, antihypertensive agents, anti-neoplastic agents, cardiovascular agents, central nervous system agents, coagulation regulators, hormones, immunizing agents, immunosuppressants and ophthalmic preparations.
[0200] Compounds can be delivered by liposome technology. Using liposomes as drug carriers can increase the therapeutic index of compounds. Liposomes are composed of natural phospholipids and can contain mixed lipid chains (e.g., egg phosphatidylethanolamine) with surfactant properties. Liposome design can adopt surface ligands for attachment to unhealthy tissues. Non-limiting examples of liposomes include multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), and large unilamellar vesicles (LUVs). Liposome physicochemical properties can be adjusted to optimize penetration through biological barriers and retention at the site of administration, and reduce the possibility of premature degradation and toxicity to non-target tissues. The optimal liposome properties depend on the route of administration: large-size liposomes show good retention after local injection, and small-size liposomes are more suitable for passive targeting. Pegylation reduces the uptake of liposomes by the liver and spleen, and increases circulation time, thereby increasing the localization at the site of inflammation due to enhanced permeability and retention (EPR) effect. In addition, the liposome surface can be modified to achieve selective delivery of encapsulated drugs to specific target cells. Non-limiting examples of targeting ligands include monoclonal antibodies, vitamins, peptides, and polysaccharides that are specific for receptors localized on the surface of cells associated with the disease.
[0201] Non-limiting examples of dosage forms suitable for use in the present disclosure include liquids, elixirs, nanosuspensions, aqueous or oily suspensions, drops, syrups, and any combination thereof. Non-limiting examples of pharmaceutically acceptable excipients suitable for use in the present disclosure include granulators, binders, lubricants, disintegrants, sweeteners, glidants, anti-adherents, antistatic agents, surfactants, antioxidants, gums, coating agents, colorants, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifiers, plant cellulose materials, and spheroidizers, and any combination thereof.
[0202] The compositions of the present disclosure can be packaged in kit form. In some embodiments, the kit includes written instructions for the administration / use of the composition. The written material may be, for example, a label. The written material may suggest conditions and methods for administration. The instructions provide the subject and the attending physician with the best guidance on obtaining the best clinical outcome from the administration of the therapy. The written material may be a label. In some embodiments, the label may be approved by a regulatory agency such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other regulatory agencies.
[0203] Administer medication.
[0204] The pharmaceutical compositions described herein may be in a unit dosage form suitable for single administration of an exact dose. In a unit dosage form, the formulation is divided into unit doses containing an appropriate amount of one or more compounds. The unit dose may be in the form of a package containing a discrete amount of formulation. A non-limiting example is a liquid in a vial or ampoule. Aqueous suspension compositions may be packaged in a single dose non-reclosable container. Multiple dose reclosable containers may be used, for example, in combination with a preservative. Parenteral injection formulations may be provided in a unit dosage form, for example, in an ampoule or in a multidose container with a preservative.
[0205] The dosage can be expressed as the amount of drug divided by the mass of the subject, e.g., milligrams of drug per kilogram of subject body weight. The compounds described herein can be administered in an amount of about 1 mg to about 2000 mg; about 100 mg to about 2000 mg; about 10 mg to about 2000 mg; about 5 mg to about 1000 mg, about 10 mg to about 500 mg, about 50 mg to about 250 mg, about 100 mg to about 200 mg, about 1 mg to about 50 mg, about 50 mg to about 100 mg, about 100 mg to about 150 mg, about 150 mg to about 200 mg, about 200 mg to about 250 mg, about 250 mg to about 300 mg, about 300 mg to about 350 mg. In the composition, the range of about 350 mg to about 400 mg, about 400 mg to about 450 mg, about 450 mg to about 500 mg, about 500 mg to about 550 mg, about 550 mg to about 600 mg, about 600 mg to about 650 mg, about 650 mg to about 700 mg, about 700 mg to about 750 mg, about 750 mg to about 800 mg, about 800 mg to about 850 mg, about 850 mg to about 900 mg, about 900 mg to about 950 mg or about 950 mg to about 1000 mg is present.
[0206] In some embodiments, the compound is administered in an amount ranging from about 5 mg / kg to about 50 mg / kg, 250 mg / kg to about 2000 mg / kg, about 10 mg / kg to about 800 mg / kg, about 50 mg / kg to about 400 mg / kg, about 100 mg / kg to about 300 mg / kg, or about 150 mg / kg to about 200 mg / kg. In some embodiments, the compound described herein can be present in the composition in a range of about 20 mg / kg to about 400 mg / kg. In some embodiments, the compound described herein can be present in the composition in a range of about 20 mg / kg to about 240 mg / kg. In some embodiments, the compound described herein can be present in the composition in a range of about 75 mg / kg to about 150 mg / kg. In some embodiments, the compound described herein can be present in the composition in a range of about 75 mg / kg to about 150 mg / kg. In some embodiments, the compound described herein can be present in the composition in a range of about 100 mg / kg to about 150 mg / kg.
[0207] In some embodiments, the compounds described herein can be present in the composition in an amount of about 75 mg / kg. In some embodiments, the compounds described herein can be present in the composition in an amount of about 100 mg / kg. In some embodiments, the compounds described herein can be present in the composition in an amount of about 150 mg / kg. In some embodiments, the compounds described herein can be present in the composition in an amount of about 200 mg / kg. In some embodiments, the compounds described herein can be present in the composition in an amount of about 250 mg / kg. In some embodiments, the compounds described herein can be present in the composition in an amount of about 400 mg / kg.
[0208] The compounds described herein can be taken in about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 125 mg. g, about 150 mg, about 175 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 11 50mg, about 1200mg, about 1250mg, about 1300mg, about 1350mg, about 1400mg, about 1450mg, about 1500mg, about 1550mg, about 1600mg, about 1650mg, about 1700mg, about 1750mg, about 1800mg, about 1850mg, about 1900mg, about 1950mg, about 2000mg, about 2050mg, about 2100mg g, about 2150 mg, about 2200 mg, about 2250 mg, about 2300 mg, about 2350 mg, about 2400 mg, about 2450 mg, about 2500 mg, about 2550 mg, about 2600 mg, about 2650 mg, about 2700 mg, about 2750 mg, about 2800 mg, about 2850 mg, about 2900 mg, about 2950 mg or about 3000 mg is present in the composition.
[0209] In some embodiments, the compounds described herein can be present in the composition in an amount of about 100 mg, about 120 mg, about 140 mg, about 160 mg, about 180 mg, about 200 mg, about 220 mg, about 240 mg, about 260 mg, about 280 mg, or about 300 mg. In some embodiments, the compounds described herein can be present in the composition in an amount of about 150 mg. In some embodiments, the compounds described herein can be present in the composition in an amount of about 170 mg. In some embodiments, the compounds described herein can be present in the composition in an amount of about 280 mg. In some embodiments, the compounds described herein can be present in the composition in an amount of about 300 mg.
[0210] Pharmacodynamic and pharmacokinetic parameters.
[0211] Pharmacokinetic and pharmacodynamic data can be obtained by various experimental techniques. Due to changes in the metabolism of the compounds of the present disclosure in different subjects, the appropriate pharmacokinetic and pharmacodynamic profile components describing a particular composition can vary. Pharmacokinetic and pharmacodynamic profiles can be based on the determination of the average parameters of a subject group. The subject group includes any reasonable number of subjects suitable for determining a representative average, for example, 5 subjects, 10 subjects, 15 subjects, 20 subjects, 25 subjects, 30 subjects, 35 subjects or more. The mean value is determined by calculating the mean value of the measurement results of all subjects of each parameter measured.
[0212] Dosages may be adjusted to achieve a desired pharmacokinetic or pharmacodynamic profile, such as a desired or effective blood profile as described herein. 150 A measure of the effectiveness of a substance in activating DNA binding of a protein target. This quantitative measure indicates the concentration of compound required to increase DNA binding activity by 50% relative to DNA binding activity in the absence of compound.
[0213] By calculating pharmacodynamic and pharmacokinetic parameters, the results of treating a human subject with a therapy can be measured. Non-limiting examples of pharmacodynamic and pharmacokinetic parameters that can be used to determine the effect of treating a subject with the therapy of the present disclosure include: a) the amount of drug administered, which can be represented as dose D; b) the dosing interval, which can be represented as τ; c) the apparent volume of drug distribution, which can be represented as the distribution volume V d , where V d =D / C0; d) The amount of drug in a given volume of tissue, which can be expressed as concentration C0 or C ss , where C0 or C ss =D / Vd; e) half-life of the drug t 1 / 2 , where t 1 / 2 =ln(2) / k e; f) the rate at which the drug is removed from the body k e , where k e =ln(2) / t 1 / 2 =CL / V d ; g) The infusion rate K required to balance the equation in , where K in =C ss .CL; h) the integral of the concentration-time curve after a single dose, which can be expressed as AUC 0-∞ ,in or in steady state, which can be expressed as AUCτ ,ss ,in The tissue volume that clears the drug per unit time can be expressed as CL (clearance rate), where CL = V d .k e = D / AUC; j) The systemically available fraction of the drug, which can be represented as f, where k) Peak tissue concentration of the drug after administration C max ; l) Drug reaches C max The time required t max m) the lowest concentration of the drug before the next dose is administered min ; and n) peak-to-trough fluctuations within a dosing interval at steady state, which can be expressed as in
[0214] The pharmacokinetic parameters can be any parameters suitable for describing the tissue concentration profile of the therapeutics of the present disclosure. For example, the pharmacokinetic profile can be obtained at a certain time after administration, such as about 0 minutes, about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, about 10 minutes, about 11 minutes, about 12 minutes, about 13 minutes, about 14 minutes, about 15 minutes, about 16 minutes, about 17 minutes, about 18 minutes, about 19 minutes, about 20 minutes, about 21 minutes, about 22 minutes, about 23 minutes, about 24 minutes, about 25 minutes, about 26 minutes, about 27 minutes, about 28 minutes, about 29 minutes, about 30 minutes, about 31 minutes, about 32 minutes, about 33 minutes, about 34 minutes, about 35 minutes, about 36 minutes, about 37 minutes, about 38 minutes, about 39 minutes, about 40 minutes, about 41 minutes, about 42 minutes, about 43 minutes, about 44 minutes, about 45 minutes, about 46 minutes, about 47 minutes, about 48 minutes, about 49 minutes, about 50 minutes, about 51 minutes, about 52 minutes, about 53 minutes, about 54 minutes, about 55 minutes, about 56 minutes, about 57 minutes, about 58 minutes, about 59 minutes, about 60 minutes, about 61 minutes, about 62 minutes, about 63 minutes, about 64 minutes, about 65 minutes, about 66 minutes, about 67 minutes, about 68 minutes, about 69 minutes, about 70 minutes, about 71 minutes, about 72 minutes, about 73 minutes, about 74 minutes, about 75 minutes, about 76 minutes, about 77 minutes minutes, about 27 minutes, about 28 minutes, about 29 minutes, about 30 minutes, about 31 minutes, about 32 minutes, about 33 minutes, about 34 minutes, about 35 minutes, about 36 minutes, about 37 minutes, about 38 minutes, about 39 minutes, about 40 minutes, about 41 minutes, about 42 minutes, about 43 minutes, about 44 minutes, about 45 minutes, about 46 minutes, about 47 minutes, about 48 minutes, about 49 minutes, about 50 minutes, about 51 minutes, about 52 minutes, about 53 minutes, about 54 minutes, about 55 minutes, about 56 minutes, about 57 minutes, about 58 minutes, about 59 minutes, about 60 minutes, about 0 hour, about 0.5 hour, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours, about 11 hours, about 11.5 hours Hours, about 12 hours, about 12.5 hours, about 13 hours, about 13.5 hours, about 14 hours, about 14.5 hours, about 15 hours, about 15.5 hours, about 16 hours, about 16.5 hours, about 17 hours, about 17.5 hours, about 18 hours, about 18.5 hours, about 19 hours, about 19.5 hours, about 20 hours, about 20.5 hours, about 21 hours, about 21.5 hours, about 22 hours, about 22.5 hours, about 23 hours, about 23.5 hours or about 24 hours.
[0215] The pharmacokinetic parameter can be any parameter suitable for describing a small molecule that binds to a non-wild-type p53 protein and causes the non-wild-type p53 protein to reform a p53 conformation that exhibits anti-cancer activity. maxIt can be, for example, not less than about 1 ng / mL; not less than about 2 ng / mL; not less than about 3 ng / mL; not less than about 4 ng / mL; not less than about 5 ng / mL; not less than about 6 ng / mL; not less than about 7 ng / mL; not less than about 8 ng / mL; not less than about 9 ng / mL; not less than about 10 ng / mL; not less than about 15 ng / mL; not less than about 20 ng / mL; not less than about 25 ng / mL; not less than about 50 ng / mL; not less than about 75 ng / mL; not less than about 100 ng / mL; not less than about 200 ng / mL; not less than about 500 ng / mL; not less than about 1,000 ng / mL. L; not less than about 2,000 ng / mL; not less than about 3,000 ng / mL; not less than about 4,000 ng / mL; not less than about 5,000 ng / mL; not less than about 6,000 ng / mL; not less than about 7,000 ng / mL; not less than about 8,000 ng / mL; not less than about 9,000 ng / mL; not less than about 10,000 ng / mL; not less than about 12,500 ng / mL; not less than about 15,000 ng / mL; not less than about 17,500 ng / mL; not less than about 20,000 ng / mL; or any other C suitable for describing the pharmacokinetic profile of the compounds described herein max . C maxIt can be, for example, about 1 ng / mL to about 50,000 ng / mL; about 1 ng / mL to about 45,000 ng / mL; about 1 ng / mL to about 40,000 ng / mL; about 1 ng / mL to about 35,000 ng / mL; about 1 ng / mL to about 30,000 ng / mL; about 1 ng / mL to about 25,000 ng / mL; about 1 ng / mL to about 20,000 ng / mL; about 1 ng / mL to about 15,000 ng / mL; about 1 ng / mL to about 10,000 ng / mL; about 5,000 ng / mL to about 50,000 ng / mL. ng / mL; about 5,000 ng / mL to about 45,000 ng / mL; about 5,000 ng / mL to about 40,000 ng / mL; about 5,000 ng / mL to about 35,000 ng / mL; about 5,000 ng / mL to about 30,000 ng / mL; about 5,000 ng / mL to about 25,000 ng / mL; about 5,000 ng / mL to about 20,000 ng / mL; about 5,000 ng / mL to about 15,000 ng / mL; about 5,000 ng / mL to about 10,000 ng / mL; about 7,500 ng / mL g / mL to about 50,000 ng / mL; about 7,500 ng / mL to about 45,000 ng / mL; about 7,500 ng / mL to about 4,000 ng / mL; about 7,500 ng / mL to about 35,000 ng / mL; about 7,500 ng / mL to about 30,000 ng / mL; about 7,500 ng / mL to about 25,000 ng / mL; about 7,500 ng / mL to about 20,000 ng / mL; about 7,500 ng / mL to about 15,000 ng / mL; about 7,500 ng / mL to about 10,000 ng / mL; about 10,000 ng / mL to about 50,000 ng / mL; about 10,000 ng / mL to about 45,000 ng / mL; about 10,000 ng / mL to about 40,000 ng / mL; about 10,000 ng / mL to about 35,000 ng / mL; about 10,000 ng / mL to about 30,000 ng / mL; about 10,000 ng / mL to about 25,000 ng / mL; about 10,000 ng / mL to about 20,000 ng / mL; or about 10,000 ng / mL to about 15,000 ng / mL.
[0216] The T of the compounds described herein maxThe T can be, for example, no greater than about 0.5 hours, no greater than about 1 hour, no greater than about 1.5 hours, no greater than about 2 hours, no greater than about 2.5 hours, no greater than about 3 hours, no greater than about 3.5 hours, no greater than about 4 hours, no greater than about 4.5 hours, no greater than about 5 hours, or any other T suitable for describing the pharmacokinetic profile of the compounds described herein. max . T max It can be, for example, about 0.1 hour to about 24 hours; about 0.1 hour to about 0.5 hour; about 0.5 hour to about 1 hour; about 1 hour to about 1.5 hours; about 1.5 hours to about 2 hours; about 2 hours to about 2.5 hours; about 2.5 hours to about 3 hours; about 3 hours to about 3.5 hours; about 3.5 hours to about 4 hours; about 4 hours to about 4.5 hours; about 4.5 hours to about 5 hours; about 5 hours to about 5.5 hours; about 5.5 hours to about 6 hours ; about 6 hours to about 6.5 hours; about 6.5 hours to about 7 hours; about 7 hours to about 7.5 hours; about 7.5 hours to about 8 hours; about 8 hours to about 8.5 hours; about 8.5 hours to about 9 hours; about 9 hours to about 9.5 hours; about 9.5 hours to about 10 hours; about 10 hours to about 10.5 hours; about 10.5 hours to about 11 hours; about 11 hours to about 11.5 hours; about 11.5 hours to about 12 hours; about 12 hours to about 12. 5 hours; about 12.5 hours to about 13 hours; about 13 hours to about 13.5 hours; about 13.5 hours to about 14 hours; about 14 hours to about 14.5 hours; about 14.5 hours to about 15 hours; about 15 hours to about 15.5 hours; about 15.5 hours to about 16 hours; about 16 hours to about 16.5 hours; about 16.5 hours to about 17 hours; about 17 hours to about 17.5 hours; about 17.5 hours to about 18 hours; about 18 hours to about 18.5 hours; to about 18.5 hours; to about 19 hours; to about 19.5 hours; to about 19.5 hours; to about 20 hours; to about 20.5 hours; to about 20.5 hours; to about 21 hours; to about 21 hours; to about 21.5 hours; to about 22 hours; to about 22 hours; to about 22.5 hours; to about 22.5 hours; to about 23 hours; to about 23.5 hours; or to about 23.5 hours.
[0217] AUC of the compounds described herein (0-inf) or AUC (last)It can be, for example, not less than about 50,000 ng hr / mL, not less than about 55,000 ng hr / mL, not less than about 60,000 ng hr / mL, not less than about 65,000 ng hr / mL, not less than about 70,000 ng hr / mL, not less than about 75,000 ng hr / mL, not less than about 80,000 ng hr / mL, not less than about 85,000 ng hr / mL, not less than about 90,000 ng hr / mL, not less than about 95,000 ng hr / mL, not less than about 100,000 ng hr / mL, not less than about 105,000 ng hr / mL, not less than about 110,000 ng hr / mL, not less than about 115,000 ng hr / mL, not less than about 120,000 ng hr / mL, not less than about 125,000 ng hr / mL, or not less than about 130,000 ng hr / mL. hr / mL, not less than about 130,000 ng hr / mL, not less than about 135,000 ng hr / mL, not less than about 140,000 ng hr / mL, not less than about 145,000 ng hr / mL, not less than about 150,000 ng hr / mL, not less than about 155,000 ng hr / mL, not less than about 160,000 ng hr / mL, not less than about 165,000 ng hr / mL, not less than about 170,000 ng hr / mL, not less than about 175,000 ng hr / mL, not less than about 180,000 ng hr / mL, not less than about 185,000 ng hr / mL, not less than about 190,000 ng hr / mL, not less than about 195,000 ng hr / mL, not less than about 200,000 ng hr / mL, or any other AUC suitable for describing the pharmacokinetic profile of the compounds described herein (0-inf) The AUC of the compounds described herein (0-inf)It can be, for example, about 1,000 ng hr / mL to about 100,000 ng hr / mL; about 40,000 ng hr / mL to about 50,000 ng hr / mL; about 50,000 ng hr / mL to about 60,000 ng hr / mL; about 60,000 ng hr / mL to about 70,000 ng hr / mL; about 70,000 ng hr / mL to about 80,000 ng hr / mL; about 80,000 ng hr / mL to about 90,000 ng hr / mL; about 90,000 ng hr / mL to about 100,000 ng hr / mL; about 100,000 ng hr / mL to about 125,000 ng hr / mL; about 125,000 ng hr / mL to about 150,000 ng hr / mL; about 150,000 ng hr / mL hr / mL to about 175,000 ng hr / mL; about 175,000 ng hr / mL to about 200,000 ng hr / mL; about 50,000 ng hr / mL to about 70,000 ng hr / mL; about 50,000 ng hr / mL to about 60,000 ng hr / mL; about 50,000 ng hr / mL to about 80,000 ng hr / mL; about 50,000 ng hr / mL to about 100,000 ng hr / mL; about 50,000 ng hr / mL to about 110,000 ng hr / mL; about 50,000 ng hr / mL to about 120,000 ng hr / mL; about 50,000 ng hr / mL to about 130,000 ng hr / mL; about 50,000 ng hr / mL to about 140,000 ng hr / mL; about 50,000ng hr / mL to about 150,000ng hr / mL; about 60,000ng hr / mL to about 110,000ng hr / mL; about 60,000ng hr / mL to about 120,000ng hr / mL; about 60,000ng hr / mL to about 130,000ng hr / mL; about 60,000ng hr / mL to about 140,000ng hr / mL; about 60,000ng hr / mL to about 150,000ng hr / mL; about 100,000ng hr / mL to about 110,000ng hr / mL; about 100,000ng hr / mL to about 120,000ng hr / mL; about 100,000ng hr / mL to about 130,000ng hr / mL; about 100,000 ng hr / mL to about 140,000 ng hr / mL; or about 100,000 ng hr / mL to about 150,000 ng hr / mL.
[0218] Example
[0219] Synthesis of Alkynyl Reagents. The reagents used in these examples can be prepared via the methods described in US Patent Publications US20220315564A1 and US20170240525A1, each of which is incorporated herein by reference in its entirety.
[0220] General synthetic method
[0221]
[0222] Propynes bearing deuterated methoxy groups were prepared by treating the corresponding phenols with deuterated methyl iodide.
[0223]
[0224] Coupling of propyne with indole iodide, such as in the presence of Pd(PPh3)4 and CuI and diisopropylamine provides compounds of the present disclosure.
[0225]
[0226] Modification of the piperidine group is achieved by treating the compound with deuterated ethylene oxide, which yields a deuterated methoxy alcohol.
[0227] The following examples contain detailed descriptions of the preparation methods of the compounds of Formula I-II. These detailed descriptions fall within the scope of the above-mentioned general synthesis procedures that form a part of the present disclosure and are used for illustration. These detailed descriptions are for illustrative purposes only and are not intended to be limiting of the scope of the present disclosure. Unless otherwise stated, all parts are by weight and temperatures are in degrees Celsius.
[0228] Example 1: Synthesis of Compound 1 and Compound 2
[0229]
[0230] The compounds were prepared via the following synthetic scheme:
[0231]
[0232] Step 1-3-Fluoropiperidin-4-one hydrochloride: 3-Fluoro-4-oxo-piperidine-1-carboxylic acid tert-butyl ester (200 g, 920.7 mmol, 1 eq) was added to HCl / EtOAc (4N, 1500 mL), and the mixture was stirred at 20°C for 5 hours. The mixture was filtered and the filter cake was collected to give crude 3-fluoropiperidin-4-one as a light yellow solid. (805 g, HCl salt).
[0233] Step 2-3-fluoro-1-methylpiperidin-4-one: At 0 ° C, methyl iodide (92.4 g, 651.1 mmol, 40.5 mL, 1 eq.) was added to a mixture of crude 3-fluoropiperidin-4-one HCl (step 1, 100 g, 651.1 mmol, 1 eq.) and K2CO3 (270.0 g, 1.95 mol, 3 eq.) in acetonitrile (1000 mL). The mixture was stirred at 30 ° C for 12 hours. The mixture was diluted with 2000 mL of DCM and filtered. The filtrate was concentrated to give a crude 3-fluoro-1-methyl-piperidin-4-one as a yellow oil. The reaction was repeated five times to obtain 600 g of the desired compound. 1 H NMR: (400MHz, DMSO-d6)δ=5.29-5.06(m,1H),3.37-3.31(m,1H),3.02-2.91(m,1 H),2.69-2.61(m,1H),2.36-2.32(m,3H),2.31-2.27(m,1H),2.24-2.17(m,2H).
[0234] Step 3-3-Fluoro-1,1-dimethyl-4-oxopiperidin-1-ium: To a solution of 3-fluoro-1-methyl-piperidin-4-one (step 2, 147.0 g, 1.12 mol, 1 eq) in acetone (1100 mL) was added methyl iodide (159.1 g, 1.1 mol, 69.8 mL, 1 eq) at 0 ° C., and the mixture was stirred at 25 ° C. for 2 hours. The mixture was concentrated to give a crude 3-fluoro-1,1-dimethyl-piperidin-1-ium-4-one as a yellow solid. The reaction was repeated four times to give a total of 1.25 kg of the desired compound.
[0235] Step 4-1-(tert-butyl)-3-fluoropiperidin-4-one: To a solution of acrylic acid (10 batches, 164.9 g, 2.29 mol, 157.07 mL, 5 equiv.) in H2O (460 mL), NaOH (10 N, 217.4 mL, 4.75 equiv.) was slowly added, and then 3-fluoro-1,1-dimethyl-piperidin-1-ium-4-one (step 3, 125 g, 457.7 mmol, 1 equiv., 1-) and tert-butylamine (669.5 g, 9.15 mol, 962.0 mL, 20 equiv.) were added. The mixture was warmed to 65 ° C and stirred for 1.5 hours. The mixture was concentrated to remove excess tert-butylamine and then extracted with DCM (3x100 mL). The organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO 2 , DCM / EA=5 / 1) to give 1-tert-butyl-3-fluoro-piperidin-4-one as brown oil (440 g in total). 1H NMR: (400MHz, DMSO-d6) δ = 5.14-4.97 (m, 1H), 3.60-3.53 (m, 1H), 3.23-3.17 (m, 1H), 2.55-2.52 (m, 1H), 2.34-2.28 (m, 3H), 1.08 (s, 7H).
[0236] Step 5-rac-N-((3S,4R)-1-(tert-butyl)-3-fluoropiperidin-4-yl)-2-iodo-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine: To a solution of 2-iodo-1-(2,2,2-trifluoroethyl)indol-4-ylamine (38 g, 100.9 mmol, 1 eq, HCl) and 1-tert-butyl-3-fluoro-piperidin-4-one (step 4, 43.7 g, 252.3 mmol, 2.5 eq) in EtOH (760 mL) was added Ti(OEt)4 (230.2 g, 1.01 mol, 209.3 mL, 10 eq) in one portion at 20°C under N2. The mixture was stirred at 50°C for 16 h. NaBH3CN (126.8g, 2.0mol, 20 equivalents) was added at 50°C and stirred for 2 hours under N2. The mixture was added to EtOAc (4000mL) and water (800mL), then saturated NaHCO3 was added to adjust the mixture to pH=9. The mixture was filtered through silica gel and extracted with EtOAc (2x1500 mL). The organic layer was washed with brine (100mL), dried over Na2SO4, filtered and concentrated to obtain residue. Residue was purified by column chromatography (SiO2, petroleum ether / EtOAc / DCM=0 / 1 / 0 to 10 / 1 / 1) to obtain a crude material. The crude material was ground for 2 hours and filtered with 150mL of MTBE / PE=5 / 1. 24.5g of S1 with 62% purity (cis) was obtained. The filtrate was concentrated to obtain about 70gL1 with 18% purity. 24.5 g of crude S1 was purified by preparative HPLC (FA conditions: column: Phenomenex luna C 18 (250*70mm, 15um); mobile phase: [water (FA)-ACN]; B%: 20%-50%, 20min) was used for purification. 70g of crude L1 was purified by preparative HPLC (FA conditions: column: Phenomenex luna C 18250mm*100mm*10mm; mobile phase: [water (FA)-ACN]; B%: 20%-50%, 25min) to give rac-N-((3S,4R)-1-(tert-butyl)-3-fluoropiperidin-4-yl)-2-iodo-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine (12.8 g, 24.3 mmol, 4.81 yield) as a yellow solid. LC-MS (ES+, m / z): 498.2 [(M+H)+]. 1 H NMR: (400MHz, DMSO-d6) δ = 7.25 (s, 2H), 6.94-6.88 (m, 1H), 6.86-6.79 (m, 1H), 6.24 (d, J = 7.7Hz, 2H), 5.3 4(d,J=8.7Hz,2H),5.08-4.94(m,4H),4.90-4.73(m,1H),3.67-3.47(m,1H),3.29-3.17(m,2H),3.01(br d,J=9.3Hz,1H),2.45-2.29(m,1H),2.21(br t,J=10.4Hz,2H),1.91-1.77(m,2H),1.77-1.69(m,2H),1.04(s,9H).
[0237] Step 6 - 3-Hydroxy-N-methyl-4-(prop-2-yn-1-ylamino)benzamide: At 0°C, under N2, BBr3 (9.2 g, 36.7 mmol, 3.5 mL, 4 equiv) was slowly added to a solution of 3-methoxy-N-methyl-4-(prop-2-yn-1-ylamino)benzamide (2.0 g, 9.2 mmol, 1 equiv) in DCM (50 mL). The mixture was stirred at 25°C for 2 hours. The reaction was slowly quenched with water (50 mL). The mixture was filtered and the filter cake was discarded. The filtrate was extracted with DCM / THF=10 / 1 (3x 50 mL). The organic layer was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated to give a residue. The residue was purified by preparative HPLC (neutral conditions: column: Welch Xtimate C 18 250*70mm*10mm; mobile phase: [water (NH4HCO3)-ACN]; B%: 5%-30%, 20min) to obtain 3-hydroxy-N-methyl-4-(prop-2-ynylamino)benzamide (0.65g, 3.02mmol, 33% yield, 95% purity) as a yellow solid. LC-MS (ES+, m / z): 205.2[(M+H)+].
[0238] Step 7 - N-methyl-4-(prop-2-ynylamino)-3-(trideuteriomethoxy)benzamide: To a solution of 3-hydroxy-N-methyl-4-(prop-2-ynylamino)benzamide (Step 6, 550.0 mg, 2.7 mmol, 1 eq) in DMF (6 mL) were added KCO (744.4 mg, 5.4 mmol, 2 eq) and trideuterio(iodo)methane (429.4 mg, 3.0 mmol, 184.3 mL, 1.1 eq) and the mixture was stirred at 25° C. After 2 h, the mixture was filtered. The filtrate was purified by preparative HPLC (neutral conditions: column: Waters Xbridge BEH C18 250*50mm*10mm; mobile phase: [water (NH4HCO3)-ACN]; B%: 15%-45%, 10 min) to give N-methyl-4-(prop-2-ynylamino)-3-(trideuterated methoxy)benzamide (260.0 mg, 1.1 mmol, 39.3% yield) as a yellow solid. LC-MS (ES+, m / z): 222.2 [(M+H)+].
[0239] Step 8 - 4-[3-[4-[[(3S,4R)-1-tert-butyl-3-fluoro-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-N-methyl-3-(trideuteriomethoxy)benzamide: To a solution of N-methyl-4-(prop-2-ynylamino)-3-(trideuteriomethoxy)benzamide (Step 7, 117.4 mg, 477.6 mmol, 90% purity, 1 eq) in DMSO (4 mL) was added i-Pr2N H (483.3 mg, 4.8 mmol, 674.93 mL, 10 eq), CuI (9.1 mg, 47.8 mmol, 0.1 eq), rac-N-[(3S,4R)-1-tert-butyl-3-fluoro-4-piperidinyl]-2-iodo-1-(2,2,2-trifluoroethyl)indol-4-ylamine (step 5, 0.25 g, 477.6 mmol, 95% purity, 1 eq) and Pd(PPh3)4 (27.6 mg, 23.9 mmol, 0.05 eq). The mixture was stirred at 45 °C for 1 hour. The mixture was diluted with EtOAc (70 mL) and saturated EDTA solution (80 mL) was added and the mixture was stirred for 1 hour. The mixture was extracted with EtOAc (2x80 mL), the organic layer was washed with brine (40 mL), dried over Na2SO4, filtered and concentrated to give a residue. The residue was purified by preparative HPLC (neutral conditions: column: C 18(250*50mm*10mm); mobile phase: [water(NH4HCO3)-ACN]; B%: 50%-70%, 10min) to give rac-4-[3-[4-[[(3S,4R)-1-tert-butyl-3-fluoro-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-N-methyl-3-(trideuterated methoxy)benzamide (0.175g, 292.49mmol, 61.25% yield) as a yellow solid. LC-MS: (ES+, m / z): 591.4[(M+H)+].
[0240] Step 7-4-[3-[4-[[(3S,4R)-1-tert-butyl-3-fluoro-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-N-methyl-3-(trideuteromethoxy)benzamide (Compound 1) and 4-[3-[4-[[(3R,4S)-1-tert-butyl-3-fluoro-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-N-methyl-3-(trideuteromethoxy)benzamide (Compound 2): Separated by chiral SFC (column: DAICELCHIRALCEL OJ (250 mm*30 mm, 10 mm); mobile phase: [0.1% NH3H2O ETOH]; B%: 43%-43%, 12 min) to give 4-[3-[4-[[(3S,4R)-1-tert-butyl-3-fluoro-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-N-methyl-3-(trideuterated methoxy)benzamide (Compound 1) [(78.0 mg, 132.0 mmol, 46.9% yield) as a yellow solid. LC-MS (ES+, m / z): 591.4 [(M+H)+]. 1H NMR: (400MHz, DMSO-d6) δ = 8.13-8.06 (m, 2H), 7.45-7.39 (m, 2H), 7.34 (d, J = 1.7Hz, 2H), 7.15 (s, 2H) ),7.00(t,J=8.0Hz,2H),6.78-6.70(m,4H),6.23(d,J=7.8Hz,2H),5.98(t,J=6.4Hz,2H),5.40(br d,J=8.7Hz,2H),4.97-4.87(m,2H),4.87-4.71(m,1H),4.31(d,J=6.2Hz,4H),3.63-3.48(m,2H),3.27-3.17(m,2H),3.01(br d, J = 11.2 Hz, 2H), 2.75 (d, J = 4.4 Hz, 3H), 2.43-2.29 (m, 1H), 2.20 (br t, J = 11.0 Hz, 2H), 1.89-1.76 (m, 2H), 1.76-1.67 (m, 2H), 1.03 (s, 19H)] and 4-[3-[4-[[(3R,4S)-1-tert-butyl-3-fluoro-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-N-methyl-3-(trideuteriomethoxy)benzamide (Compound 2) (80.0 mg, 135.0 mmol, 48.0% yield) as a yellow solid. LC-MS(ES+,m / z):591.4[(M+H)+]. 1 H NMR: (400MHz, DMSO-d6)δ=8.09(br d,J=4.5Hz,2H),7.44-7.39(m,2H),7.34(d,J=1.7Hz,2H),7.15(s,2H),7.00(t,J=8 .0Hz,2H),6.78-6.70(m,4H),6.23(d,J=7.7Hz,2H),5.97(t,J=6.3Hz,2H),5.40(br d,J=8.6Hz,2H),4.88(br s,2H),4.87-4.71(m,1H),4.31(d,J=6.3Hz,4H),3.62-3.47(m,2H),3.21(br t,J=10.8Hz,2H),3.00(br d,J=9.4Hz,1H),2.75(d,J=4.4Hz,6H),2.43-2.30(m,1H),2.20(br t,J=10.8Hz,2H),1.89-1.76(m,2H),1.76-1.67(m,2H),1.02(s,9H).
[0241] Example 2: Synthesis of 4-[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-N-methyl-3-(trideuterated methoxy)benzamide (Compound 3)
[0242]
[0243] To a solution of N-methyl-4-(prop-2-ynylamino)-3-(trideuteromethoxy)benzamide (Example 1, Step 7, 77.0 mg, 313.0 mmol, 90% purity, 1 eq) in DMSO (1 mL) were added i-Pr2NH (316.8 mg, 3.13 mmol, 442.39 mL, 10 eq), CuI (6.0 mg, 31.3 mmol, 0.1 eq), N-[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]-2-iodo-1-(2,2,2-trifluoroethyl)indol-4-ylamine (150.0 mg, 313.03 mmol, 95% purity, 1 eq) [prepared by a method similar to that described in Example 1, Step 5] and Pd(PPh3)4 (18.1 mg, 15.7 mmol, 0.05 eq). The mixture was stirred at 45 °C for 1 hour. The mixture was diluted with EtOAc (40 mL) and saturated EDTA solution (40 mL) was added. The mixture was stirred for 1 h and then extracted with EtOAc (2x40 mL). The organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by preparative HPLC (neutral conditions: column: Waters Xbridge PrepOBD C18 150*40mm*10mm; mobile phase: [water (NH4HCO3)-ACN]; B%: 35%-65%, 8 min) to give 4-[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-N-methyl-3-(trideuterated methoxy)benzamide (Compound 3) (65.0 mg, 117.5 mmol, 37.6% yield) as a yellow solid. LC-MS: (ES+, m / z): 549.3 [(M+H)+]. 1H NMR: (400MHz, DMSO-d6) δ = 8.14-8.05 (m, 2H), 7.46-7.38 (m, 2H), 7.34 (d, J = 1.8Hz, 2H), 7.17 (s, 2H), 7.00(t,J=8.0Hz,2H),6.80-6.69(m,4H),6.24(d,J=7.9Hz,2H),5.98(t,J=6.3Hz,2H),5.49(d,J=8.6 Hz,2H),4.98-4.88(m,2H),4.87-4.70(m,1H),4.31(d,J=6.3Hz,2H),3.64-3.45(m,1H),3.09-2.96(m ,2H),2.83-2.71(m,4H),2.32-2.15(m,4H),2.12-2.01(m,1H),1.98-1.86(m,2H),1.75-1.59(m,1H).
[0244] Example 3: Synthesis of rac-N-[(3S,4R)-3-fluoro-1-(trideuteromethyl)-4-piperidinyl]-2-[3-[4-methylsulfonyl-2-(trideuteromethoxy)anilino]prop-1-ynyl]-1-(2,2,2-trifluoroethyl)indol-4-ylamine (Compound 4)
[0245]
[0246] Step 1 - tert-Butyl 3-fluoro-4-[[2-iodo-1-(2,2,2-trifluoroethyl)indol-4-yl]amino]piperidine-1-carboxylate: To a solution of 2-iodo-1-(2,2,2-trifluoroethyl)indol-4-ylamine (15 g, 39.70 mmol, 1 eq.) and tert-butyl 3-fluoro-4-oxo-piperidine-1-carboxylate (43.12 g, 198.48 mmol, 5 eq.) in DCE (150 mL) and AcOH (450 mL) was added sodium triacetoxyborohydride (12.62 g, 59.54 mmol, 1.5 eq.) in three equal portions (half an hour each), and the mixture was stirred at 25 °C for 0.5 hours. The mixture was poured into H2O (1 L) at 0°C and basified with saturated Na2CO3 aqueous solution, pH=8, then extracted with DCM (500 mLx3). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl 3-fluoro-4-[[2-iodo-1-(2,2,2-trifluoroethyl)indol-4-yl]amino]piperidine-1-carboxylate (30 g, crude).
[0247] Step 2-tert-Butyl (3S,4R)-3-fluoro-4-[[2-iodo-1-(2,2,2-trifluoroethyl)indol-4-yl]amino]piperidine-1-carboxylate: The residue from step 1 [cis:trans=3.5:1] was purified by preparative HPLC (FA conditions; column: Xtimate C 18 10m 250mm*80mm; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 55%-75%, 22min) was purified to obtain the cis form, (3S,4R)-3-fluoro-4-[[2-iodo-1-(2,2,2-trifluoroethyl)indol-4-yl]amino]piperidine-1-carboxylic acid tert-butyl ester (11 g, 20.32 mmol, 36.67% yield).
[0248] Step 3 - N-[(3S,4R)-3-fluoro-4-piperidinyl]-2-iodo-1-(2,2,2-trifluoroethyl)indol-4-ylamine: To a solution of (3S,4R)-3-fluoro-4-[[2-iodo-1-(2,2,2-trifluoroethyl)indol-4-yl]amino]piperidine-1-carboxylic acid tert-butyl ester (step 2, 3.5 g, 6.47 mmol, 1 eq.) in DCM (6 mL) was added TFA (3 mL). The mixture was stirred at 25 °C for 10 min. The reaction was quenched by the addition of aqueous Na2CO3 to adjust to pH = 8, and the mixture was extracted with DCM (100 mL x 3). The combined organic layers were washed with brine (50 mL x 2), dried over [Na2SO4], filtered and concentrated under reduced pressure to give a residue (2.3 g, crude) which was used directly in the next step. LC-MS (ES + ,m / z):442.0;[(M+H) + ] 1 H NMR (400MHz, DMSO-d6)δ=7.25-7.28(s,1H),6.88-6.94(t,1H),6.80-6.85(d,1H),6.22-6.27(d,1H),5.37-5.42(d,1H),4.95-5.04 (q,2H),4.62-4.79(d,1H),3.60-3.73(m,1H),3.08-3.14(t,1H),2.93-3.00(d,1H),2.69-2.85(t,1H),2.56(dd,J=38.8Hz,J=14Hz 1H),1.61-1.78(m,2H).
[0249] Step 4 - N-[(3S,4R)-3-fluoro-1-(trideuteriomethyl)-4-piperidinyl]-2-iodo-1-(2,2,2-trifluoroethyl)indol-4-ylamine: To a solution of N-[(3S,4R)-3-fluoro-4-piperidinyl]-2-iodo-1-(2,2,2-trifluoroethyl)indol-4-ylamine (step 3, 500.00 mg, 1.13 mmol, 1.0 equiv) in DMF (5 mL) was added Cs2CO3 (1.11 g, 3.40 mmol, 3 equiv) and trideuterio(iodo)methane (160.85 mg, 1.13 mmol, 69.04 μL, 1 equiv). The mixture was stirred at 25 ° C for 16 hours, and then trideuterated (iodine) methane (80.43 mg, 566.63 mmol, 34.52 mL, 0.5 equivalent) was added. Under N2 atmosphere, the mixture was stirred at 25 ° C for 14 hours. The reaction mixture was quenched by adding H2O (70 mL) and extracted with EtOAc (50 mL x 3). The combined organic layer was washed with brine 20 mL (10 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to obtain residue. The residue was purified by column chromatography (SiO2, DCM / MeOH=1 / 0 to 50 / 1) to give N-[(3S,4R)-3-fluoro-1-(trideuteromethyl)-4-piperidinyl]-2-iodo-1-(2,2,2-trifluoroethyl)indol-4-ylamine (380.00 mg, 646.81 mmol, 57.08% yield, 78.00% purity). LC-MS (ES) + ,m / z):459.0[(M+H) + ].
[0250] Step 5 -rac-N-[(3S,4R)-3-fluoro-1-(trideuteromethyl)-4-piperidinyl]-2-[3-[4-methylsulfonyl-2-(trideuteromethoxy)anilino]prop-1-ynyl]-1-(2,2,2-trifluoroethyl)indol-4-ylamine (Compound 4): To a solution of 4-methylsulfonyl-N-prop-2-ynyl-2-(trideuteromethoxy)aniline [prepared similarly to that described in Step 2 of Example 6] (74.24 mg, 306.38 mmol, 1.2 equiv) in DMSO (3 mL) was added. i-Pr2NH (258.36 mg, 2.55 mmol, 360.83 mL, 10 equiv), N-[(3R, 4S)-3-fluoro-1-(trideuteromethyl)-4-piperidinyl]-2-iodo-1-(2,2,2-trifluoroethyl)indol-4-ylamine (step 4, 150 mg, 255.32 mmol, 1 equiv), CuI (9.73 mg, 51.06 mmol, 0.2 equiv) and Pd(PPh3)4 (14.75 mg, 12.77 mmol, 0.05 equiv) were added to the reaction mixture. The mixture was degassed and purged 3 times with N2. The mixture was stirred at 50 °C for 1 hour. The reaction was quenched by adding EDTA 40 mL and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (10 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO2, DCM: MeOH = 10: 1), and the residue was purified by preparative HPLC (FA conditions; column: Phenomenex Luna C 18 200*40mm*10mm; mobile phase: [water (0.2% FA)-ACN]; B%: 20%-60%, 10min) and then purified to obtain rac-N-[(3S,4R)-3-fluoro-1-(trideuteromethyl)-4-piperidinyl]-2-[3-[4-methylsulfonyl-2-(trideuteromethoxy)anilino]prop-1-ynyl]-1-(2,2,2-trifluoroethyl)indol-4-ylamine (Compound 4) (180 mg, 314.33 mmol, 93.26% yield, 100% purity). LC-MS (ES+, m / z): 573.1 [(M+H) + ] 1HNMR (400MHz, DMSO-d6)δ=7.36-7.41(d,1H),7.23-7.26(s,1H),7.16-7.20(s,1H),6.97-7.04(t ,1H),6.87-6.91(d,1H),6.71-6.77(d,1H),6.46-6.52(t,1H),6.20-6.27(d,1H),5.46-5.53(d,1 H),4.73-4.98(m,3H),4.32-4.39(d,2H),3.58-3.62(m,1H),3.09(s,3H),3.00-3.04(m,1H),2.8 1(d,J=10.15Hz,1H),2.17-2.26(m,1H),2.08-2.14(t,1H),1.87-1.96(m,1H),1.67-1.72(d,1H).
[0251] Example 4: Synthesis of 4-[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-methoxy-N-(trideuterated methyl)benzamide (Compound 5)
[0252]
[0253] Step 1-t N-[2-methoxy-4-(trideuteriomethylcarbamoyl)phenyl]-N-prop-2-ynyl-carbamic acid tert-butyl ester: To a mixture of trideuteriomethylamine hydrochloride (101.65 mg, 1.44 mmol, 1.1 eq.) and 4-[tert-butoxycarbonyl(prop-2-ynyl)amino]-3-methoxy-benzoic acid (400 mg, 1.31 mmol, 1.0 eq.) in DMF (4 mL) was added HOBt (531.07 mg, 3.93 mmol, 3.0 eq.), EDCI (753.43 mg, 3.93 mmol, 3.0 eq.), TEA (1.06 g, 10.48 mmol, 1.46 mL, 8.0 eq.) at 25° C. and stirred for 2 hours. The aqueous phase was extracted with EtOAc (3×30 mL) and water (30 mL). The combined organic phases were washed with brine (3 x 30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude material was purified by preparative TLC (SiO2, DCM / MeOH = 10:1) to give the desired compound (360 mg, 1.12 mmol, 85.50% yield) as a white oil. LC-MS (ES) + ,m / z):266.2[(M-55) + ].
[0254] Step 2-tert-Butyl N-[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynyl]-N-[2-methoxy-4-(trideuterated methylcarbamoyl)phenyl]carbamate (1-2): At 25° C. under N 2 , N-[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]-2-iodo-1-(2,2,2-trifluoroethyl)indol-4-ylamine (Example 2, 120 mg, 263.60 mmol, 1.0 equiv) and N -[2-methoxy-4-(trideuterated methylcarbamoyl)phenyl]-N-prop-2-ynyl-carbamic acid tert-butyl ester (step 1, 84.72mg, 263.60mmol, 1.0 equivalent) was added once in a mixture in DMSO (3mL) CuI (5.02mg, 26.36mmol, 0.1 equivalent), N-isopropylpropan-2-amine (266.74mg, 2640.00mmol, 10.0 equivalent) and Pd(PPh3)4 (15.23mg, 13.18mmol, 0.1 equivalent) and the reaction was stirred for 1 hour. The mixture was poured into EDTA (saturated) (30mL) and stirred for 120min. The aqueous phase was extracted with EtOAc (3x30 mL) and the combined organic phase was washed with brine (3x30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude material was purified by preparative TLC (SiO 2 , DCM / MeOH=10:1) to afford the desired compound (150 mg, 231.23 mmol, 87.72% yield) as a white oil.
[0255] Step 3-4-[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-methoxy-N-(trideuterated methyl)benzamide (Compound 5).
[0256]
[0257] HCl / EtOAc (4M, 2 mL, 34.6 equiv) was added in one portion to tert-butyl N-[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynyl]-N-[2-methoxy-4-(trideuterated methylcarbamoyl)phenyl]carbamate (step 2, 150 mg, 231.23 mmol, 1.0 equiv) at 25 °C and stirred for 1 hour. The mixture was poured into NaHCO3(saturated) (10 mL). The aqueous phase was extracted with EtOAc (3x20 mL). The combined organic phases were washed with brine (3x20 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude material was passed through preparative HPLC, column: Welch Xtimate C 18 150*25mm*5mm; mobile phase: [water (0.04% HCl)-ACN]; B%: 30%-55%, 10 min] to obtain compound 5 (27.1 mg, 48.55 mmol, 21.00% yield, 98.1% purity) as a yellow solid. LC-MS (ES + ,m / z):549.3[(M+H) + ]. 1 H NMR (400MHz, DMSO-d6) δ = 8.06 (s, 1H), 7.42 (dd, J = 8.19, 1.59Hz, 1H), 7.35 (d, J = 1.71Hz, 1H), 7.16 (s, 1H), 7.00 (t,J=7.94Hz,1H),6.80-6.65(m,2H),6.24(d,J=7.70Hz,1H),5.97(t,J=6.36Hz,1H),5.48(d,J=8.68Hz,1H),4 .99-4.64(m,3H),4.31(d,J=6.12Hz,2H),3.84(s,3H),3.65-3.45(m,1H),3.02(t,J=10.33Hz,1H),2.80(d,J=1 1.13Hz, 1H), 2.30-2.15 (m, 4H), 2.09 (t, J = 11.08Hz, 1H), 1.92 (d, J = 12.10, 3.78Hz, 1H), 1.69 (d, J = 9.90Hz, 1H).
[0258] Example 5: Synthesis of 4-[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-(trideuteromethoxy)-N-(trideuteromethyl)benzamide (Compound 6)
[0259]
[0260] Step 1-4-[tert-butoxycarbonyl(prop-2-ynyl)amino]-3-methoxy-benzoic acid: At 20°C, to a mixture of 4-[tert-butoxycarbonyl(prop-2-ynyl)amino]-3-methoxy-benzoic acid methyl ester (2 g, 6.26 mmol, 1.0 equiv) in MeOH (15 mL) and H2O (5 mL) was added NaOH (751.47 mg, 18.79 mmol, 3.0 equiv) in one portion and stirred for 4 hours. HCl (5 M) was added to the solution to adjust to pH = 5. The aqueous phase was extracted with EtOAc (3x30 mL). The combined organic phases were washed with brine (3x30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude material was purified by preparative TLC (SiO 2 , DCM / MeOH=10:1) to give the acid (1.8 g, 5.90 mmol, 94.13% yield) as a white solid.
[0261] Step 2 - N-[2-methoxy-4-(trideuteriomethylcarbamoyl)phenyl]-N-prop-2-ynyl-carbamic acid tert-butyl ester: To a mixture of trideuteriomethylamine hydrochloride (457.42 mg, 6.48 mmol, 1.1 equiv) and 4-[tert-butoxycarbonyl(prop-2-ynyl)amino]-3-methoxy-benzoic acid (step 1, 1.8 g, 5.90 mmol, 1.0 equiv) in DMF (25 mL) at 25 °C were added HOBt (2.39 g, 17.69 mmol, 3.0 equiv), EDCI (3.39 g, 17.69 mmol, 3.0 equiv), TEA (4.77 g, 47.16 mmol, 6.56 mL, 8.0 equiv) in one portion and the reaction was stirred for 2 h. The aqueous phase was extracted with EtOAc (3x50 mL) and water (50 mL). The combined organic phases were washed with brine (3x50 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (column height: 250 mm, diameter: 100 mm, 100-200 mesh silica gel, petroleum ether / EtOAc=80:20 to 70:30) to give deuterated amide (1.7 g, 5.29 mmol, 89.72% yield) as a white oil.
[0262] Step 3-3-methoxy-4-(prop-2-ynylamino)-N-(trideuterated methyl)benzamide: At 25°C, to a mixture of N-[2-methoxy-4-(trideuterated methylcarbamoyl)phenyl]-N-prop-2-ynyl-carbamic acid tert-butyl ester (step 2, 1.85 g, 5.76 mmol, 1.0 equiv) in DCM (20 mL) was added TFA (6.16 g, 54.02 mmol, 4 mL, 9.4 equiv) in one portion and stirred for 2 hours. The mixture was cooled to 0°C. The residue was poured into NaOH (2M) to pH = 8. The aqueous phase was extracted with EtOAc (3x30 mL). The combined organic phases were washed with brine (3×30 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo to give 3-methoxy-4-(prop-2-ynylamino)-N-(trideuteriomethyl)benzamide (1.1 g, crude) as a yellow solid.
[0263] Step 4 - 3-Hydroxy-4-(prop-2-ynylamino)-N-(trideuteromethyl)benzamide: To a mixture of 3-methoxy-4-(prop-2-ynylamino)-N-(trideuteromethyl)benzamide (step 3, 1.1 g, 4.97 mmol, 1.0 eq.) in DCM (15 mL) was added BBr (1.87 g, 7.46 mmol, 718.51 mL, 1.5 eq.) at 0 °C and stirred for 1 hour. The residue was poured into ice water (10 mL) and stirred for 20 min. The solution was then added to NaHCO (saturated) (10 mL). The aqueous phase was extracted with DCM (3x20 mL) and water (20 mL). The combined aqueous phases were lyophilized. The dried crude product was purified by preparative HPLC [column: Phenomen[ex Luna C 18 200*40mm*10mm; mobile phase: [water (0.2% FA)-ACN]; B%: 1%-50%, 8min] to obtain the hydroxy compound (400mg, 1.93mmol, 38.82% yield) as a white solid. LC-MS (ES + ,m / z):208.2[(M+1) + ].
[0264] Step 5 - 4-(prop-2-ynylamino)-3-(trideuteriomethoxy)-N-(trideuteriomethyl)benzamide: To a mixture of 3-hydroxy-4-(prop-2-ynylamino)-N-(trideuteriomethyl)benzamide (step 4, 350 mg, 1.69 mmol, 1.0 eq) in DMF (6 mL) was added KCO (466.81 mg, 3.38 mmol, 2.0 eq), trideuterio(iodo)methane (293.77 mg, 2.03 mmol, 126.08 mL, 1.2 eq) in one portion at 25°C and stirred for 1 hour. The aqueous phase was extracted with ethyl acetate (3x20 mL) and water (30 mL). The combined organic phases were washed with brine (3x20 mL), dried over anhydrous NaSO, filtered and concentrated in vacuo. The crude material was purified by preparative TLC to give the deuterated methoxy compound (320 mg, 1.43 mmol, 84.48% yield) as a white oil.
[0265] Step 6 - 4-[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-(trideuteriomethoxy)-N-(trideuteriomethyl)benzamide (Compound 6): At 25° C. under N 2 , N-[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]-2-iodo-1-(2,2,2-trifluoroethyl)indol-4-ylamine (Example 2, 250 mg, 549.17 mmol, 1.0 equiv) and 4-(propanol)-2-ynylamino]-3-(trideuteriomethoxy)-N-(trideuteriomethyl)benzamide were added. To a mixture of 2-(trideuteromethoxy)-N-(trideuteromethyl)benzamide (step 5, 184.76 mg, 823.76 mmol, 1.5 eq.) in DMSO (5 mL) was added CuI (10.46 mg, 54.92 mmol, 0.1 eq.), N-isopropylpropan-2-amine (555.71 mg, 5.49 mmol, 776.13 mL, 10.0 eq.), Pd(PPh3)4 (31.73 mg, 27.46 mmol, 0.1 eq.) and stirred for 3 hours. The residue was poured into EDTA (saturated) (30 mL) and stirred for 120 min. The aqueous phase was extracted with ethyl acetate (3x30 mL). The combined organic phases were washed with brine (3x30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude material was purified by preparative HPLC [column: Waters Xbridge Prep OBD C 18150*40mm*10mm; mobile phase: [water (0.05% NH3H2O+10mM NH4HCO3)-ACN]; B%: 35%-60%, 8min] to obtain compound 6 (109.85mg, 199.15mmol, 36.26% yield, 100% purity) as a white solid. LC-MS (ES + ,m / z):552.3[(M+1) + ]. 1 H NMR (400MHz, DMSO-d6) δ = 8.07 (s, 1H), 7.41 (d, J = 7.28Hz, 1H), 7.34 (s, 1H), 7.16 (s, 1 H),7.00(s,1H),6.74(s,2H),6.23(d,J=5.52Hz,1H),5.99(s,1H),5.50(d,J=7.28Hz ,1H),5.02-4.69(m,3H),4.31(s,2H),3.66-3.46(m,1H),3.02(s,1H),2.80(d,J=8.6 0Hz,1H),2.26(d,J=12.35Hz,1H),2.08(s,1H),1.92(d,J=11.03Hz,1H),1.70(s,1H). 1 H NMR (400MHz, methanol-d4) δ = 7.43 (dd, J = 8.31, 1.96Hz, 1H) 7.36 (d, J = 1.96Hz, 1H) 7.07 (t, J = 8.00Hz ,1H)6.89(s,1H)6.92-6.88(m,1H)6.83(d,J=8.20Hz,1H)6.72(d,J=8.32Hz,1H)6.34(d,J=7.7 0Hz,1H)4.91-4.78(s,1H)4.73(q,J=8.88Hz,2H)4.35(s,2H)3.73-3.55(m,1H)3.25-3.11(m, 1H)2.97-2.89(m,1H)2.39(d,J=13.20Hz,1H)2.31(s,3H)2.29-2.20(m,1H)2.01-1.88(m,2H).
[0266] Example 6: Synthesis of 3-methoxy-1-[4-(2-{4-[4-(methylsulfonyl)-2-(trideuteromethoxy)phenyl]-1-butynyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-ylamino)-1-piperidinyl]-2-propanol (Compound 7)
[0267]
[0268] This compound was prepared via the following synthetic scheme:
[0269]
[0270] Step 1: Preparation of 4-methylsulfonyl-N-prop-2-ynyl-2-(hydroxy)aniline: 4-Methylsulfonyl-N-prop-2-ynyl-2-hydroxyaniline was prepared from 4-methylsulfonyl-N-prop-2-ynyl-2-methoxyaniline by a method similar to that described in Step 6 of Example 1.
[0271] Step 2: Preparation of 4-methylsulfonyl-N-prop-2-ynyl-2-(trideuteromethoxy)aniline: To a mixture of 4-methylsulfonyl-N-prop-2-ynyl-2-(hydroxy)aniline (step 1, 0.15 g, 665.89 mmol, 1 eq.) in DMF (5 mL) was added KCO (184.06 mg, 1.33 mmol, 2 eq.) and trideutero(iodo)methane (96.52 mg, 665.89 mmol, 41.43 mL, 1 eq.). The mixture was stirred at 50 °C for 1 hour. The mixture was diluted with H2O 100 mL and then extracted with EtOAc (50 mL x 2). The combined organic layers were washed with H2O (100 mL x 2) and saturated saline solution (100 mL x 2) in sequence. The organic layer was then dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by preparative TLC (SiO 2 , PE:EA=1:1) to give the alkyne, 4-methylsulfonyl-N-prop-2-ynyl-2-(trideuterated methoxy)aniline as a yellow oil (0.13 g, 536.51 mmol, 80.57% yield).
[0272] Step 3: Preparation of 1-{4-[2-iodo-1-(2,2,2-trifluoroethyl)-1H-indol-4-ylamino]-1-piperidinyl}-3-methoxy-2-propanol: To a mixture of N-4-piperidinyl[2-iodo-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amine (prepared by a method similar to that described in Example 1, Step 5, 5 g x 2, 1 eq) in ACN (100 mL) was added KCO (3 eq) and 2-(methoxymethyl)oxirane (5 eq). The mixture was stirred at 50 °C for 5 hours. The mixture was diluted with H0 (500 mL) and then extracted with EtOAc (200 mL x 2). The combined organic layers were washed with H0 (500 mL x 2) and saturated saline solution (500 mL x 2) in sequence, then dried over anhydrous NaSO, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO 2 , petroleum ether / EtOAc = 1 / 1 to 0: 1) to obtain 1-{4-[2-iodo-1-(2,2,2-trifluoroethyl)-1H-indol-4-ylamino]-1-piperidinyl}-3-methoxy-2-propanol (10 g, 19.56 mmol) as a red solid (82.77% yield).
[0273] Step 4: Preparation of 3-methoxy-1-[4-(2-{4-[4-(methylsulfonyl)-2-(trideuteromethoxy)phenyl]-1-butynyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-ylamino)-1-piperidinyl]-2-propanol (Compound 7): To a mixture of 4-methylsulfonyl-N-prop-2-ynyl-2-(trideuteromethoxy)aniline (Step 2, 56.87 mg, 234.69 mmol, 1.5 equiv) in DMSO (3 mL) were added i-Pr2NH (158.32 mg, 1.56 mmol, 221.12 mL, 10 equiv) and CuI (5.96 mg, 31.29 mmol, 0.2 equiv). Then add 1-{4-[2-iodo-1-(2,2,2-trifluoroethyl)-1H-indol-4-ylamino]-1-piperidinyl}-3-methoxy-2-propanol (80mg, 156.46mmol, 1 equivalent) and Pd(PPh3)4(18.08mg, 15.65mmol, 0.1 equivalent) and under N2, the mixture is stirred at 25 DEG C for 1 hour.At 25 DEG C, the reaction mixture is quenched by adding EDTA saturated solution (50mL) and EtOAc (25mL).The resulting mixture is extracted with EtOAc (50mLx2), washed with H2O (100mLx2) and saturated saline solution (100mLx2) successively.The organic layer is dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain residue. The residue was purified by preparative TLC (SiO2, DCM:MeOH=10:1), and then further purified by preparative HPLC (FA conditions; column: Waters Atlantis T3150*30*5mm; mobile phase: [water (0.225% FA)-ACN]; B%: 25%-50%, 13 min). 3-Methoxy-1-[4-(2-{4-[4-(methylsulfonyl)-2-(trideuteromethoxy)phenyl]-1-butynyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-ylamino)-1-piperidinyl]-2-propanol (Compound 7) (23.8 mg, 37.85 mmol, 24.19% yield, 99.5% purity) was obtained as a white solid. LC-MS (ES + ,m / z):626.2[(M+1) + ].
[0274] Example 7: Synthesis of 3-(trideuterated methoxy)-1-[4-(2-{4-[2-methoxy-4-(methylsulfonyl)phenyl]-1-butynyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-ylamino)-1-piperidinyl]-2-propanol (Compound 8)
[0275]
[0276] Step 1: Preparation of 2-[(trideuterated)methoxymethyl]oxirane: To a solution of (2-oxiranyl)methanol (300 mg, 4.05 mmol, 267.86 mL, 1 eq.) in DMF (2 mL) was added NaOH (161.99 mg, 4.05 mmol, 1 eq.), CD3I (587.04 mg, 4.05 mmol, 251.95 mL, 1 eq.). The reaction was stirred at 25°C for 2 hours. The crude 2-[(trideuterated)methoxymethyl]oxirane was used directly in the next step.
[0277]
[0278] Step 2: Preparation of 3-(trideuterated methoxy)-1-[4-(2-{4-[2-methoxy-4-(methylsulfonyl)phenyl]-1-butynyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-ylamino)-1-piperidinyl]-2-propanol (Compound 8): At 25°C, N-4-piperidinyl (2-{4-[2-methoxy-4-(methylsulfonyl)phenyl]-1-butynyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-ylamino)-1-piperidinyl]-2-propanol was added to the mixture. To a mixture of 2-[(trideuterated)methoxymethyl]oxirane (step 1, 102.27 mg, 1.12 mmol, 3 equiv) and K2CO3 (103.41 mg, 748.23 mmol, 2 equiv) in DMF (3 mL) was added 2-[(trideuterated)methoxymethyl]oxirane (step 1, 102.27 mg, 1.12 mmol, 3 equiv) and K2CO3 (103.41 mg, 748.23 mmol, 2 equiv). The mixture was heated to 50 °C and stirred for 12 h. The reaction was quenched by saturated NH4Cl (20 mL) and then extracted with EtOAc (20 mLx3). The combined organic phases were washed with brine (20 mLx3), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by TLC (DCM:MeOH=10:1, Rf=0.5) and then by preparative HPLC (column: Luna C 18 100*30 5m; mobile phase: [water (0.225% FA)-ACN]; B%: 10%-40%, 15min) was re-purified. The desired compound (11.6 mg, 18.09 mmol, 4.84% yield, 97.606% purity) was obtained as a light yellow solid. LC-MS (ES + ,m / z):626.2[(M+1) + ].
[0279] Example 8: Synthesis of (1-trideuterated methyl-4-piperidinyl)(2-{4-[2-methoxy-4-(methylsulfonyl)phenyl]-1-butynyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amine (Compound 9)
[0280]
[0281] This compound was prepared via the following synthetic scheme.
[0282]
[0283] Step 1: Preparation of 1-(trideuterated methyl)-4-piperidinyl[2-iodo-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amine: To a mixture of N-4-piperidinyl[2-iodo-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amine (Example 6 Step 3, 0.2 g, 472.57 mmol, 1 eq.) in DMF (5 mL) was added K2CO3 (130.63 mg, 945.15 mmol, 2 eq.) and trideuterated (iodo)methane (82.20 mg, 567.09 mmol, 35.28 mL, 1.2 eq.). The mixture was stirred at 50° C. for 1 hour. The reaction mixture was diluted with H2O (50 mL) and then extracted with EtOAc (25 mL×2). The combined organic layers were washed with H2O (100 mL x 2) and saturated saline solution (100 mL x 2) in sequence, then dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO2, DCM: MeOH = 10: 1). The desired compound (70 mg, 159.00 mmol, 33.64% yield) was obtained as a yellow solid.
[0284] Step 2: Preparation of (1-trideuteromethyl-4-piperidinyl)(2-{4-[2-methoxy-4-(methylsulfonyl)phenyl]-1-butynyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amine (Compound 9): To a mixture of 2-methoxy-4-methylsulfonyl-N-prop-2-ynyl-phenylamine (40.76 mg, 170.35 mmol, 1.5 equiv) in DMSO (3 mL) were added i-Pr2NH (114.92 mg, 1.14 mmol, 160.50 mL, 10 equiv) and CuI (4.33 mg, 22.71 mmol, 0.2 equiv). Indole (50 mg, 113.57 mmol, 1 eq.) and Pd(PPh3)4 (13.12 mg, 11.36 mmol, 0.1 eq.) from step 1 were added to the resulting mixture. The mixture was stirred at 25 °C for 1 hour under N2. The reaction was quenched at 25 °C by adding a saturated solution of EDTA (50 mL) and EtOAc (25 mL), then extracted with EtOAc (25 mLx2), washed with H2O (50 mLx2) and a saturated salt solution (50 mLx2) in turn. The resulting organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by preparative TLC (SiO2, DCM: MeOH = 10: 1). The residue was purified by preparative HPLC (neutral conditions; column: Waters Xbridge 150*25 5m; mobile phase: [water (10 mM NH4HCO3)-CAN]; B%: 40%-70%, 10 min). The desired compound (24.6 mg, 44.06 mmol, 98.8% purity) was obtained as a white solid. LC-MS (ES + ,m / z):552.2[(M+1) + ].
[0285] Example 9: Synthesis of Rac-N-((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)-2-(3-((2-(methoxy-d3)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine (Compound 10)
[0286]
[0287] To a mixture of 4-methylsulfonyl-N-prop-2-ynyl-2-(trideuterated methoxy)aniline (95.81 mg, 395.40 mmol, 1.2 eq) in DMSO (2 mL) was added DIPEA (333.42 mg, 3.30 mmol, 465.68 mL, 10 eq) and CuI (62.75 mg, 329.50 mmol, 1 eq). To the resulting mixture was added rac-N-[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]-2-iodo-1-(2,2,2-trifluoroethyl)indol-4-ylamine (Example 2, 150 mg, 329.50 mmol, 1 eq) and Pd(PPh3)4 (38.08 mg, 32.95 mmol, 0.1 eq). The reaction was stirred at 25°C for 1 hour under N2. The reaction was diluted with 30mL EtOAc and poured into 50mL saturated EDTA, then stirred at 25 ℃ for 1 hour. The mixture was extracted with EtOAc (40mLx3). The organic layer merged was washed with salt water (40mLx3), through Na2SO4 drying, filtered and concentrated under reduced pressure to obtain residue. Residue was passed through preparation HPLC (column: Kromasil 150*25mm*10mm; mobile phase: [water (0.04%NH3H2O+10mM NH4HCO3)-ACN]; B%: 30%-60%, 20min) purifying. Rac-N-((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)-2-(3-((2-(methoxy-d3)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine (Compound 10) (67.7 mg, 118.85 mmol, 36.07% yield, 100% purity) was obtained as a light yellow solid. LC-MS (ES + ,m / z):571.2[(M+1) + ].
[0288] Example 10: Synthesis of [(3S,4R)-3-fluoro-1-methyl-4-piperidinyl](2-{4-[2-methoxy-4-(methylsulfonyl)phenyl]-1-butynyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amine (Compound 11)
[0289]
[0290] The subject compound was prepared via the following synthetic scheme.
[0291]
[0292] Specifically, to a solution of alkyne, 4-methylsulfonyl-N-prop-2-ynyl-2-(trideuteromethoxy)aniline (150.10 mg, 619.47 mmol, 1.2 eq) in DMSO (3 mL) were added i-Pr2NH (783.55 mg, 7.74 mmol, 1.09 mL, 15 eq), [(3S,4R)-3-fluoro-1-methyl-4-piperidinyl][2-iodo-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amine (250 mg, 516.22 mmol, 1 eq), CuI (19.66 mg, 103.24 mmol, 0.2 eq) and Pd(PPh3)4 (59.65 mg, 51.62 mmol, 0.1 eq). The reaction was stirred at 25°C for 2 h under N2. The reaction was poured into EDTA (saturated aqueous solution, 20mL). The mixture was extracted with EtOAc 60mL (20mL x 3). The combined organic layer was washed with brine 60mL (20mLx3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=1 / 1 to EtOAc:MeOH:TEA=10:1:0.5), and then purified by preparative HPLC (column: WatersXbridge Prep OBD C18 150*40mm*10mm; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 45%-65%, 8min) to obtain the desired compound (110.1mg, 192.70mmol, 37.33% yield, 99.7% purity) as a pink solid. LC-MS (ES + ,m / z):571.2[(M+1) + ].
[0293] Example 11: Characterization of Compounds of the Present Disclosure
[0294] The samples were analyzed using mass spectrometry. The mass-to-charge ratio (m / z) detected and the relative abundance of the m / z values were used to determine the percentage of deuterated and non-deuterated compounds in the sample.
[0295] Example 12: In vitro DNA binding activity assay
[0296] The ability of the compounds of the present disclosure to stabilize p53 Y220C and increase the DNA binding activity of p53 Y220C was measured by homogeneous time-resolved fluorescence (HTRF) assay. The recombinant p53 Y220C with a His tag used in the HTRF assay was expressed in Escherichia coli (E. coli). The recombinant protein is a truncated mutant containing only amino acids 94-312 of p53, which includes the DNA binding domain (DBD) of p53 (SEQ ID NO.: 1). The DNA binding ability of p53 Y220C with a His tag was tested with a consensus sequence of DNA (a DNA duplex having a sequence of 5¢-ATTAGGCATGTCTAGGCATGTCTAGG-3¢; SEQ ID NO.: 2). SEQ ID NO.: 2 was then conjugated to a biotin label and used for activity assays.
[0297] The binding of recombinant His-tagged p53Y220C protein and biotin-labeled consensus DNA was measured using fluorescence resonance energy transfer (FRET). For the FRET assay, the binding between the p53 mutant and the DNA sequence was measured by detecting the fluorescence of the interaction between an anti-His antibody conjugated to allophycocyanin (APC) and streptavidin conjugated to europium to detect the biotin-labeled DNA.
[0298] The test compound was prepared as a 4.5 mM stock solution in dimethyl sulfoxide (DMSO). The compounds disclosed herein were used to test the stability of p53 Y220C and increase the DNA binding activity of p53 Y220C. The stock solution was then serially diluted 3 times in DMSO, and 1.2 μL of the diluted solution was added to each well of a 384-well polypropylene black plate. 30 μL of a 181 nM solution of recombinant p53 Y220C protein with a His tag and 12.1 nM of an APC-conjugated anti-His tag antibody were added to each well containing the test compound.
[0299] As a background control, 30 mL of assay buffer 1 containing 12.1 nM APC anti-His antibody was also added to the second set of serially diluted compound plates. The test and control samples were rotated at 1200 rpm for 1 minute and incubated at room temperature for 15 minutes. The samples were then incubated for another 60 min at 27°C or 29°C. Five microliters of 311 nM biotin-labeled common DNA (SEQ ID NO.: 2) and 13.03 nM europium-conjugated streptavidin in assay buffer 2 (50 mM Tris-HCl (pH 7.4); 75 mM KCl; and 0.2 mg / mL BSA) were added to each well of the test plate and control plate. The plate was rotated at 1200 rpm for 1 minute and incubated at room temperature for 20 minutes. The assay signal was monitored by reading the excitation at 340 nm and the emitted fluorescence at 615 nm and 665 nm on a plate reader.
[0300] The normalized time-resolved fluorescence resonance energy transfer (TR-FRET) assay signal (Rn) was calculated by the following formula: Rn = [(A-Ba-CD) / (D-Bd)] (Dc-Bd), where A is the fluorescence intensity of the sample at 665 nm; D is the fluorescence intensity of the sample at 615 nm; Ba and Bd are the plate background readings at 665 nm and 615 nm, respectively; and Dc is the fluorescence intensity of 1.8 nM Eu-SA in the assay buffer at 615 nm.
[0301] The crosstalk factor (C) was determined by the following formula: C = (Ac-Ba) / (Dc-Bd), where Ac is the fluorescence intensity of 1.8 nM Eu-labeled anti-FLAG antibody in assay buffer at 665 nm. The percent activation of protein DNA binding in the presence of the disclosed compounds compared to the absence of the compounds is given by SC 150 Values are presented, indicating the concentration of compound required to increase DNA binding activity by 50%. TM or ActivityBase TM To calculate SC 150 value.
[0302] Table 1: +++ = 0 nM <SC 150 <10nM;++=10nM <SC 150 <50nM
[0303] Compound <![CDATA[SC 150 ]]> 4 +++ 5 +++ 6 +++ 7 ++ 8 ++ 9 ++ 10 +++ 11 +++
[0304] Example 13: Pharmacokinetic Analysis
[0305] The pharmacokinetics (PK) of deuterated and control compounds were measured after 2-phase single oral (PO) administration to male cynomolgus monkeys. Compound and metabolite levels were monitored up to 48 hours after dosing.
[0306] A group of 3 non-naive male cynomolgus monkeys were used in this 2-phase study, with a 5-day washout period between each phase. Animals in phase 1 or 2 were administered the compound at 25 mg / kg by a single oral administration. The vehicle used for oral studies was a 2% (w / v) hydroxypropylcellulose (HPC) w / v aqueous solution ["vehicle"]. Animals that were fasting (overnight) were administered PO. The fasting time before administration was at least 12 hours, but the total fasting time did not exceed 20 hours. On the day of dosing in phase 1, the body weight of male animals ranged from 2.28 to 3.32 kg. All animals received a single oral gavage administration in each phase.
[0307] Compound formulations were prepared according to the following procedure: 257.0 mg of Compound C (4-[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-N-methyl-3-(methyloxy)benzamide) was added to a pre-calibrated beaker, mixed manually with 1 mL of vehicle, and stirred for 5 min to produce a uniform opaque suspension. An additional 40 mL of vehicle was added, mixed manually, and stirred for 5 min to produce a uniform opaque suspension. An additional 9.218 mL of vehicle was added and stirred overnight to produce a uniform opaque suspension. 260.3 mg of Compound 3 (4-[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-N-methyl-3-(trideuterated methoxy)benzamide) was added to a pre-calibrated beaker and the test article with 49.978 mL of vehicle was manually mixed and stirred for 30 min to produce a homogenous opaque suspension. The formulation was stored at room temperature for up to 15 days after preparation.
[0308] The detailed dosing and sampling protocols are described in the table below.
[0309] Table 2.
[0310]
[0311] The concentration of the compounds in all dosing solutions was determined by UPLC-UV [ACQUITY UPLC, ACQUITY UPLC BEH C8 1.7 μm 2.1×100 mm column, mobile phase A: 0.1% FA and 2 mM HCOONH4 in water / ACN (v:v, 95:5), mobile phase B: 0.1% FA and 2 mM HCOONH4 in ACN / water (v:v, 95:5). Three aliquots were taken from the bottom, middle, and top regions of the PO dosing solution.
[0312] Plasma samples were collected at 0.25, 0.5, 1, 2, 4, 8, 12, 24 and 48 hours after dosing in phases 1 and 2. Blank plasma: Whole blood was collected from available livestock into commercially available test tubes containing K2-EDTA on wet ice and processed into plasma. Plasma was pooled for use as blank monkey plasma. PK plasma: At each time point, approximately 0.5 mL of blood was collected from each study animal via a peripheral blood vessel. The actual time of each sample collection was recorded. The deviation of the sampling time was less than 1 minute at the time point before dosing to 1 hour after dosing, and the deviation of the sampling time at the time point 1 hour after dosing was less than 5% of the nominal time. All blood samples were transferred to commercial test tubes (Jiangsu Kangjian medicalsupplies Co., Ltd.) containing K2-EDTA (0.85-1.15 mg) and placed on wet ice until processed into plasma. Plasma samples were prepared within 1 hour after collection by centrifuging blood samples at about 2-8 ° C and 3200 × g for 10 minutes. Approximately 0.1 mL × 2 aliquots of plasma samples (one for BA and the other for backup) at each time point were transferred to labeled polypropylene microcentrifuge tubes and stored frozen in a freezer to maintain at -60°C or lower until LC-MS / MS analysis. The concentrations of compounds and metabolites in plasma samples were determined by liquid chromatography-tandem mass spectrometry (LC-MS / MS) method [triple quadrupole 6500+, ESI (+) ionization mode, MRM detection mode]. Non-compartmental pharmacokinetic analysis of plasma concentrations of compounds and metabolites in study animals was performed using Phoenix WinNonlin software (version 6.3 or higher, Pharsight). The linear / logarithmic trapezoidal rule was applied when obtaining PK parameters. Individual plasma concentration values below the lower limit of quantification (LLOQ) were excluded from PK parameter calculations. Nominal dose levels and nominal sampling times were used in the calculation of all pharmacokinetic parameters.
[0313] After oral administration of 25 mg / kg of the compound to male cynomolgus monkeys, the area under the plasma concentration-time curve (AUC 0-24) values were 66942±25843 and 107359±29193 ng·h / mL, respectively. This shows that the AUC increased by about 60% compared with compound C. In addition, the C max The values were 5667±3003 and 10017±4175 ng / mL, respectively, while the T values of control compound C and compound 3 were max The mean PK parameters of the compounds are summarized below.
[0314] Table 3.
[0315]
[0316] The mean PK parameters of the parent compound and the two glucuronidated metabolites are summarized in Table 4. Compound 3 showed a reduction in both glucuronidated metabolites [70% and 10%].
[0317] Table 4 Biotransformation of compounds
[0318]
[0319] Implementation
[0320] The following non-limiting embodiments provide illustrative examples of the present disclosure but do not limit the scope of the present disclosure.
[0321] Embodiment 1. A compound of formula I:
[0322]
[0323] in:
[0324] -R 1 selected from aryl, heteroaryl and heterocyclic groups, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the group consisting of hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic group, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R 21 and ester groups;
[0325] -R 2 is an alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl group, each of which is independently unsubstituted or substituted with one, two or three substituents selected from the following:
[0326] hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R 21 and an ester group; or hydrogen, -C(O)R 21 、-C(O)OR 21 、-C(O)NR 21 R 22 、-OR 21 ,
[0327] -SR 21 、-NR 21 R 22 、-NR 21 C(O)R 22 or -OC(O)R 21 ;
[0328] -R 3 It is H;
[0329] -R 4 is a heterocyclic group substituted by one, two or three substituents selected from the group consisting of a halogen group, a hydroxyl group, a thiol group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group
[0330] -P(O)R 21 and an ester group; and
[0331] - Each R 21 and R 22 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclic, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the group consisting of a halogen group, a hydroxyl group, a thiol group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group and an ester group; and
[0332] wherein the compound comprises at least one deuterium or deuterated [D] group;
[0333] wherein each position specifically designated as D, deuterated, or deuterium has at least about 10% deuterium incorporation;
[0334] or a pharmaceutically acceptable salt thereof.
[0335] Embodiment 2. The compound according to embodiment 1, wherein R 1 is an aryl group substituted by one, two or three substituents selected from the group consisting of an alkylsulfonyl group, an alkoxy group, an alkylaminocarbonyl group, a deuterated alkoxy group and a (deuterated alkyl)aminocarbonyl group.
[0336] Embodiment 3. The compound according to embodiment 2, wherein R 1 is phenyl substituted by one, two or three substituents selected from the group consisting of: C 1-4 Alkylsulfonyl, C 1-4 Alkoxy, C 1-4 Alkylaminocarbonyl, deuterated C 1-4 Alkoxy and (deuterated C 1-4 alkyl)aminocarbonyl.
[0337] Embodiment 4. The compound according to embodiment 3, wherein R 1 is phenyl substituted by one, two or three substituents selected from the group consisting of methylsulfonyl, methoxy, methylaminocarbonyl, trideuteromethoxy or (trideuteromethyl)aminocarbonyl.
[0338] Embodiment 5. The compound according to embodiment 1, wherein R 2 It is an alkyl group which is unsubstituted or substituted by a halogen group.
[0339] Embodiment 6. The compound according to embodiment 5, wherein R 2 It is C 1-4 Halogenated alkyl.
[0340] Embodiment 7. The compound according to embodiment 6, wherein R 2 It is 1,1,1-trifluoroethyl.
[0341] Embodiment 8. The compound according to embodiment 1, wherein R 4 is 4-piperidinyl which is unsubstituted or substituted by one, two or three substituents selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 Alkoxy-(hydroxy)-C 1-4 alkyl.
[0342] Embodiment 9. The compound according to embodiment 8, wherein R 4is 4-piperidinyl substituted with fluorine and one or two further substituents selected from the group consisting of methyl, trideuteromethyl, tert-butyl, 2-hydroxy-methoxypropyl and 2-hydroxy-trideuteromethoxypropyl.
[0343] Embodiment 10. The compound according to embodiment 1, having the formula
[0344]
[0345] in:
[0346] -R 2 is a C1-C4 haloalkyl group,
[0347] -R 25 selected from hydrogen, hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, alkylsulfonyl, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, deuterated alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic, acyl, acyloxy, carbamate, acyl
[0348] Amine group, deuterated alkylamide group, urea group, epoxy group, -P(O)R 21 and ester group; -R 26 is selected from the group consisting of hydrogen, hydroxy, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, deuterated alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic, acyl, acyloxy, carbamate, amide, deuterated amide, urea, epoxy, -P(O)R 21 and ester groups;
[0349] -R 27 selected from the group consisting of hydrogen groups substituted by hydroxyl groups, sulfhydryl groups, halogen groups, amino groups, nitro groups, nitroso groups, cyano groups, azido groups, sulfoxide groups, sulfone groups, sulfonamide groups, carboxyl groups, carboxaldehyde groups, imine groups, alkyl groups, haloalkyl groups, alkenyl groups, haloalkenyl groups, alkynyl groups, haloalkynyl groups, alkoxy groups, aryl groups, aryloxy groups, aralkyl groups, arylalkoxy groups, heterocyclic groups, acyl groups, acyloxy groups, carbamate groups, amide groups, urea groups, epoxy groups, -P(O)R 21 and ester groups;
[0350] -R 28is selected from hydrogen, hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, deuterated alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R 21 and ester groups;
[0351] The condition is R 25 , R 26 , R 27 or R 28 One or more of is a deuterated group;
[0352] or a pharmaceutically acceptable salt thereof.
[0353] Embodiment 11. The compound according to embodiment 10, wherein:
[0354] -R 2 It is 1,1,1-trifluoroethyl;
[0355] -R 25 is selected from C1-C4 alkylaminocarbonyl, deuterated C1-C4 alkylaminocarbonyl or C1-C4 alkylsulfonyl;
[0356] -R 26 is C1-C4 alkoxy or deuterated C1-C4 alkoxy;
[0357] -R 27 is a hydrogen radical or a fluorine radical; and
[0358] -R 28 It is selected from C1-C4 alkyl, deuterated C1-C4 alkyl, C1-C4 alkoxy-C1-C4 alkyl optionally substituted with hydroxyl, or deuterated C1-C4 alkoxy-C1-C4 alkyl optionally substituted with hydroxyl.
[0359] Embodiment 12. The compound according to embodiment 11, wherein:
[0360] -R 25 is methylsulfonyl, methylaminocarbonyl or trideuterated methylaminocarbonyl;
[0361] -R 26 is methoxy or trideuterated methoxy; and
[0362] -R 28 It is selected from methyl, tert-butyl, deuterated methyl, 2-hydroxy-1-methoxypropyl or 1-trideuterated methoxy-2-hydroxypropyl.
[0363] Embodiment 13. The compound according to Embodiment 10, wherein the compound has the formula:
[0364]
[0365]
[0366] Embodiment 14. A method of inducing apoptosis in a cell, the method comprising contacting the cell with a therapeutically effective amount of a compound that binds to a p53 mutant, wherein the compound is a compound according to any one of Embodiments 1-13.
[0367] Embodiment 15. The method of embodiment 14, wherein the compound increases the ability of the p53 mutant to bind to DNA.
[0368] Embodiment 16. The method according to embodiment 14, wherein the p53 mutant is p53 Y220C.
[0369] Embodiment 17. The method according to embodiment 14, wherein the compound induces a conformational change in the p53 mutant.
[0370] Embodiment 18. The method of embodiment 14, wherein the compound increases the stability of the biologically active conformation of the p53 mutant relative to the stability of the biologically active conformation of the p53 mutant in the absence of the compound.
[0371] Embodiment 19. A method of treating cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of Embodiments 1-13, wherein the compound has a SC of less than 1 mM for p53 Y220C. 150 Values, as measured by homogeneous time-resolved fluorescence (HTRF) assay.
[0372] Embodiment 20. The method of embodiment 19, wherein the administration is intravenous administration.
[0373] Embodiment 21. The method of embodiment 19, wherein the administration is oral administration.
[0374] Embodiment 22. The method according to Embodiment 9, wherein the administration is intratumoral administration.
[0375] Embodiment 23. The method of embodiment 19, wherein the therapeutically effective amount is about 20 mg / kg to about 400 mg / kg.
[0376] Embodiment 24. The method of Embodiment 19, wherein the cancer is breast cancer.
[0377] Embodiment 25. The method of Embodiment 19, wherein the cancer is lung cancer.
[0378] Embodiment 26. The method of embodiment 19, wherein the compound increases the stability of the biologically active conformation of the p53 mutant relative to the stability of the biologically active conformation of the p53 mutant in the absence of the compound.
[0379] Embodiment 27. The method of embodiment 19, wherein the compound has a SC 150 value.
[0380] Embodiment A1. A composition comprising a population of molecules, wherein the population of molecules has a mass of at least 1 μg, wherein at least 10% of the molecules in the population of molecules each independently comprise a deuterium atom, wherein each molecule is a compound of Formula I:
[0381]
[0382] in:
[0383] -R 1 is selected from aryl, heteroaryl and heterocyclic groups, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the group consisting of hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic group, acyl, acyloxy, amino
[0384] Formate group, amide group, urea group, epoxy group, -P(O)R 21 and ester group; -R 2 Selected from hydrogen, -C(O)R 21 、-C(O)OR 21 、-C(O)NR 21 R 22 、-OR 21 、-SR 21 ,
[0385] -NR 21 R 22 、-NR 21 C(O)R 22 、-OC(O)R 21, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclic group, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the following: hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide group, sulfone group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic group, acyl, acyloxy, carbamate group, amide group, urea group, epoxy group, -P(O)R 21 and ester groups;
[0386] -R 3 It is H;
[0387] -R 4 is a heterocyclic group substituted by one, two or three substituents selected from the group consisting of a halogen group, a hydroxyl group, a sulfhydryl group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group, -P(O)R 21 and an ester group; and
[0388] - Each R 21 and R 22 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclic, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the group consisting of a halogen group, a hydroxyl group, a thiol group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group and an ester group; and
[0389] wherein the compound is optionally substituted with at least one deuterated [D] group;
[0390] or a pharmaceutically acceptable salt thereof.
[0391] Embodiment A2. A composition according to Embodiment A1, wherein at least 50% of the molecules in the population of molecules each independently comprise a deuterium atom.
[0392] Embodiment A3. A composition according to Embodiment A1, wherein at least 90% of the molecules in the population of molecules each independently comprise a deuterium atom.
[0393] Embodiment A4. A composition according to Embodiment A1, wherein at least 95% of the molecules in the population of molecules each independently comprise a deuterium atom.
[0394] Embodiment A5. The composition of Embodiment A1, wherein at least 99% of the molecules in the population of molecules each independently comprise a deuterium atom.
[0395] Embodiment A6. A composition according to Embodiment A1, wherein at least 10% of the molecules in the population of molecules each independently comprise a deuterium atom at a common position.
[0396] Embodiment A7. A composition according to Embodiment A1, wherein at least 50% of the molecules in the population of molecules each independently comprise a deuterium atom at a common position.
[0397] Embodiment A8. The composition of Embodiment A1, wherein at least 90% of the molecules in the population of molecules each independently comprise a deuterium atom at a common position.
[0398] Embodiment A9. A composition according to Embodiment A1, wherein at least 95% of the molecules in the population of molecules each independently comprise a deuterium atom at a common position.
[0399] Embodiment A10. The composition of Embodiment A1, wherein at least 99% of the molecules in the population of molecules each independently comprise a deuterium atom at a common position.
[0400] Embodiment A11. A composition according to embodiment A1, wherein at least 10% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0401] Embodiment A12. A composition according to embodiment A1, wherein at least 50% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0402] Embodiment A13. A composition according to embodiment A1, wherein at least 90% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0403] Embodiment A14. A composition according to embodiment A1, wherein at least 95% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0404] Embodiment A15. A composition according to embodiment A1, wherein at least 99% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0405] Embodiment A16. A composition according to Embodiment A1, wherein the population of molecules has a mass of at least 1 mg.
[0406] Embodiment A17. A composition according to Embodiment A1, wherein the population of molecules has a mass of at least 100 mg.
[0407] Embodiment A18. A composition according to Embodiment A1, wherein the population of molecules has a mass of at least 1 kg.
[0408] Embodiment A19. A composition according to Embodiment A1, wherein the population of molecules has a mass of at least 100 kg.
[0409] Embodiment A20. The composition of Embodiment A1, wherein the population of molecules has a therapeutically effective mass for treating cancer.
[0410] Embodiment B1. A composition comprising a population of molecules, wherein the population of molecules has a mass of at least 1 μg, wherein if a mass spectrum of the population is obtained in a mass spectrometry experiment, the mass spectrometry experiment determines that at least 10% of the molecules in the population of molecules each independently contain a deuterium atom, wherein each molecule is a compound of Formula I:
[0411]
[0412] in:
[0413] -R 1 selected from aryl, heteroaryl and heterocyclic groups, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the group consisting of hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic group, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R 21 and ester groups;
[0414] -R 2 is an alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl group, each of which is independently unsubstituted or substituted with one, two or three substituents selected from the following:
[0415] hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic, acyl, acyloxy, carbamate, amide, urea, epoxy, -P(O)R 21 and an ester group; or hydrogen, -C(O)R 21 、-C(O)OR 21 、-C(O)NR 21 R 22 、-OR 21 ,
[0416] -SR 21 、-NR 21 R 22 、-NR 21 C(O)R 22 or -OC(O)R 21 ;
[0417] -R 3 It is H;
[0418] -R 4 is a heterocyclic group substituted by one, two or three substituents selected from the group consisting of a halogen group, a hydroxyl group, a sulfhydryl group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group,
[0419] -P(O)R 21 and an ester group; and
[0420] - Each R 21 and R 22 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclic, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the group consisting of a halogen group, a hydroxyl group, a thiol group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group and an ester group; and
[0421] wherein the compound optionally comprises at least one deuterated [D] group;
[0422] or a pharmaceutically acceptable salt thereof.
[0423] Embodiment B2. The composition of Embodiment B1, wherein said mass spectrometry experiment determines that at least 50% of the molecules in said population of molecules each independently comprise a deuterium atom.
[0424] Embodiment B3. The composition of Embodiment B1, wherein the mass spectrometry experiment determines that at least 90% of the molecules in the population of molecules each independently contain a deuterium atom.
[0425] Embodiment B4. The composition of Embodiment B1, wherein the mass spectrometry experiment determines that at least 95% of the molecules in the population of molecules each independently contain a deuterium atom.
[0426] Embodiment B5. The composition of Embodiment B1, wherein the mass spectrometry experiment determines that at least 99% of the molecules in the population of molecules each independently contain deuterium atoms.
[0427] Embodiment B6. The composition of Embodiment B1, wherein the mass spectrometry experiment determines that at least 10% of the molecules in the population of molecules each independently contain three deuterium atoms.
[0428] Embodiment B7. The composition of Embodiment B1, wherein the mass spectrometry experiment determines that at least 50% of the molecules in the population of molecules each independently contain three deuterium atoms.
[0429] Embodiment B8. The composition of Embodiment B1, wherein the mass spectrometry experiment determines that at least 90% of the molecules in the population of molecules each independently contain three deuterium atoms.
[0430] Embodiment B9. The composition of Embodiment B1, wherein the mass spectrometry experiment determines that at least 95% of the molecules in the population of molecules each independently contain three deuterium atoms.
[0431] Embodiment B10. The composition of Embodiment B1, wherein the mass spectrometry experiment determines that at least 99% of the molecules in the population of molecules each independently contain three deuterium atoms.
[0432] Embodiment B11. A composition according to Embodiment B1, wherein the population of molecules has a mass of at least 1 mg.
[0433] Embodiment B12. A composition according to Embodiment B1, wherein the population of molecules has a mass of at least 100 mg.
[0434] Embodiment B13. A composition according to Embodiment B1 wherein the population of molecules has a mass of at least 1 kg.
[0435] Embodiment B14. A composition according to Embodiment B1 wherein the population of molecules has a mass of at least 100 kg.
[0436] Embodiment B15. The composition of Embodiment B1, wherein the population of molecules has a therapeutically effective mass for treating cancer.
[0437] Embodiment B16. A composition according to Embodiment B1, wherein if a sample of the molecular population in CDCl3 is used on a 500 MHz NMR instrument 1 H NMR experiments were performed to provide results that were compared with those obtained on the 500 MHz NMR instrument for a similar population of molecules containing the natural isotopic abundance of deuterium in CDCl3. 1 H NMR spectra, then the NMR experiment indicates that at least 10% of the molecules in the population of molecules independently comprise a CD3 group at a common position.
[0438] Embodiment B17. The composition of Embodiment B16, wherein the NMR experiment indicates that at least 50% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0439] Embodiment B18. A composition according to Embodiment B16, wherein the NMR experiment indicates that at least 90% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0440] Embodiment B19. A composition according to Embodiment B16, wherein the NMR experiment indicates that at least 95% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0441] Embodiment B20. A composition according to Embodiment B16, wherein the NMR experiment indicates that at least 99% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0442] Embodiment C1. A composition comprising a population of molecules, wherein the population of molecules has a mass of at least 1 μg, wherein if a mass spectrum of the population is obtained in a mass spectrometry experiment, the mass spectrometry experiment identifies a molecular ion having a mass of 549.3±0.5, wherein each molecule is:
[0443]
[0444] or a pharmaceutically acceptable salt thereof.
[0445] Embodiment C2. A composition according to embodiment C1, wherein the population of molecules has a mass of at least 1 mg.
[0446] Embodiment C3. A composition according to embodiment C1, wherein the population of molecules has a mass of at least 100 mg.
[0447] Embodiment C4. A composition according to Embodiment C1, wherein the population of molecules has a mass of at least 1 kg.
[0448] Embodiment C5. A composition according to Embodiment C1, wherein the population of molecules has a mass of at least 100 kg.
[0449] Embodiment C6. A composition according to embodiment C1, wherein the population of molecules has a therapeutically effective mass for treating cancer.
[0450] Embodiment C7. A composition according to Embodiment C1, wherein if a sample of the molecular population in CDCl3 is used to perform a 500 MHz NMR 1 H NMR experiments were performed to provide results that were compared with those obtained on the 500 MHz NMR instrument for a similar population of molecules containing the natural isotopic abundance of deuterium in CDCl3. 1 Compared with the H NMR spectrum, the NMR experiments indicated that the molecular ion represented a structure having a CD3 group.
[0451] Embodiment D1. A method for treating cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises a population of molecules, wherein at least 10% of the molecules in the population of molecules each independently comprise a deuterium atom, wherein each molecule in the population of molecules is a compound that binds to a non-wild-type p53 protein and causes the non-wild-type p53 protein to reform a p53 conformation that exhibits anti-cancer activity.
[0452] Embodiment D2. A method according to embodiment D1, wherein the non-wild-type p53 protein comprises a mutation at Y220C.
[0453] Embodiment D3. The method of embodiment D1, wherein the compound selectively binds to the non-wild-type p53 protein compared to the wild-type p53 protein.
[0454] Embodiment D4. A method according to embodiment D1, wherein at least 50% of the molecules in the population of molecules each independently contain a deuterium atom.
[0455] Embodiment D5. A method according to embodiment D1, wherein at least 90% of the molecules in the population of molecules each independently contain deuterium atoms.
[0456] Embodiment D6. A method according to embodiment D1, wherein at least 95% of the molecules in the population of molecules each independently contain deuterium atoms.
[0457] Embodiment D7. A method according to embodiment D1, wherein at least 99% of the molecules in the population of molecules each independently contain deuterium atoms.
[0458] Embodiment D8. A method according to embodiment D1, wherein at least 10% of the molecules in the population of molecules each independently contain a deuterium atom at a common position.
[0459] Embodiment D9. A method according to embodiment D1, wherein at least 50% of the molecules in the population of molecules each independently contain a deuterium atom at a common position.
[0460] Embodiment D10. A method according to embodiment D1, wherein at least 90% of the molecules in the population of molecules each independently contain a deuterium atom at a common position.
[0461] Embodiment D11. A method according to embodiment D1, wherein at least 95% of the molecules in the population of molecules each independently contain a deuterium atom at a common position.
[0462] Embodiment D12. A method according to embodiment D1, wherein at least 99% of the molecules in the population of molecules each independently contain a deuterium atom at a common position.
[0463] Embodiment D13. A method according to embodiment D1, wherein at least 10% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0464] Embodiment D14. A method according to embodiment D1, wherein at least 50% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0465] Embodiment D15. A method according to embodiment D1, wherein at least 90% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0466] Embodiment D16. A method according to embodiment D1, wherein at least 95% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0467] Embodiment D17. A method according to embodiment D1, wherein at least 99% of the molecules in the population of molecules each independently comprise a CD3 group at a common position.
[0468] Embodiment E1. A method for treating cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises a population of molecules, wherein if a mass spectrum of the population is obtained in a mass spectrometry experiment, the mass spectrometry experiment determines that at least 10% of the molecules in the population of molecules each independently contain a deuterium atom, wherein each molecule in the population of molecules is a compound that binds to a non-wild-type p53 protein and causes the non-wild-type p53 protein to reform a p53 conformation that exhibits anti-cancer activity.
[0469] Embodiment E2. The method of Embodiment E1, wherein the non-wild-type p53 protein comprises a mutation at Y220C.
[0470] Embodiment E3. The method of Embodiment E1, wherein the compound selectively binds to the non-wild-type p53 protein compared to the wild-type p53 protein.
[0471] Embodiment E4. A method according to Embodiment El, wherein the mass spectrometry experiment determines that at least 50% of the molecules in the population of molecules each independently contain a deuterium atom.
[0472] Embodiment E5. A method according to Embodiment El, wherein the mass spectrometry experiment determines that at least 90% of the molecules in the population of molecules each independently contain deuterium atoms.
[0473] Embodiment E6. A method according to Embodiment El, wherein the mass spectrometry experiment determines that at least 95% of the molecules in the population of molecules each independently contain deuterium atoms.
[0474] Embodiment E7. A method according to Embodiment E1, wherein the mass spectrometry experiment determines that at least 99% of the molecules in the population of molecules each independently contain deuterium atoms.
[0475] Embodiment E8. A method according to Embodiment El, wherein the mass spectrometry experiment determines that at least 10% of the molecules in the population of molecules each independently contain three deuterium atoms.
[0476] Embodiment E9. A method according to Embodiment E1, wherein the mass spectrometry experiment determines that at least 50% of the molecules in the population of molecules each independently contain three deuterium atoms.
[0477] Embodiment E10. The method of Embodiment E1, wherein the mass spectrometry experiment determines that at least 90% of the molecules in the population of molecules each independently contain three deuterium atoms.
[0478] Embodiment E11. A method according to Embodiment E1, wherein the mass spectrometry experiment determines that at least 95% of the molecules in the population of molecules each independently contain three deuterium atoms.
[0479] Embodiment E12. A method according to Embodiment E1, wherein the mass spectrometry experiment determines that at least 99% of the molecules in the population of molecules each independently contain three deuterium atoms.
[0480] Embodiment E13. The method of Embodiment E1, wherein the cancer is ovarian cancer.
[0481] Embodiment E14. The method of Embodiment E1, wherein the cancer is breast cancer.
[0482] Embodiment E15. The method of Embodiment E1, wherein the cancer is pancreatic cancer.
[0483] Embodiment E16. The method of Embodiment E1, wherein the cancer is lung cancer.
[0484] Embodiment E17. The method of Embodiment E1, wherein the therapeutically effective amount of the pharmaceutical composition comprises from about 500 mg to about 2000 mg of the compound.
[0485] Embodiment E18. The method of Embodiment E1, wherein the therapeutically effective amount of the pharmaceutical composition comprises about 600 mg of the compound.
[0486] Embodiment E19. Embodiment E18. The method according to Embodiment E1, wherein the therapeutically effective amount of the pharmaceutical composition comprises about 1200 mg of the compound.
[0487] Embodiment E20. Embodiment E18. The method according to Embodiment E1, wherein the therapeutically effective amount of the pharmaceutical composition comprises about 2000 mg of the compound.
[0488] Embodiment F1. A method for treating cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises a population of molecules, wherein if a mass spectrum of the population is obtained in a mass spectrometry experiment, the mass spectrometry experiment identifies a molecular ion having a mass of 548.58±0.5, wherein each molecule in the population of molecules is a compound that binds to a non-wild-type p53 protein and causes the non-wild-type p53 protein to reform a p53 conformation that exhibits anti-cancer activity.
[0489] Embodiment F2. A method according to Embodiment F1, wherein if a sample of the molecular population in CDCl3 is used on a 500 MHz NMR instrument 1 H NMR experiments were performed to provide results that were compared with those obtained on the 500 MHz NMR instrument for a similar population of molecules containing the natural isotopic abundance of deuterium in CDCl3. 1 Compared with the H NMR spectrum, the NMR experiments indicated that the molecular ion represented a structure having a CD3 group.
Claims
1. A composition comprising a population of molecules, wherein the population of molecules has a mass of at least 1 μg, wherein at least 10% of the molecules in the population of molecules each independently contain a deuterium atom, wherein each molecule is a compound of formula (I): in: -R 1 selected from aryl, heteroaryl and heterocyclic groups, each of which is independently unsubstituted or substituted with one, two or three substituents selected from the group consisting of hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic group, acyl, acyloxy, carbamate, amide, urea, epoxy and ester groups; -R 2 Selected from hydrogen, -C(O)R 21 、-C(O)OR 21 、-C(O)NR 21 R 22 、-OR 21 、-SR 21 , -NR 21 R 22 、-NR 21 C(O)R 22 、-OC(O)R 21 , alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclic group, each of which is independently unsubstituted or substituted with one, two or three substituents selected from the group consisting of hydroxy, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclic group, acyl, acyloxy, carbamate, amide, urea, epoxy and ester groups; -R 3 It is H; -R 4 is a heterocyclic group substituted by one, two or three substituents selected from the group consisting of a halogen group, a hydroxyl group, a sulfhydryl group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group and an ester group; and - Each R 21 and R 22 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclic, each of which is independently unsubstituted or substituted by one, two or three substituents selected from the group consisting of a halogen group, a hydroxyl group, a thiol group, a halogen, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a urea group, an epoxy group and an ester group; or a pharmaceutically acceptable salt thereof, wherein said compound is optionally substituted with at least one deuterium.
2. The composition according to claim 1, wherein R 1 is an aryl group substituted by one, two or three substituents selected from the group consisting of an alkylsulfonyl group, an alkoxy group, an alkylaminocarbonyl group, a deuterated alkoxy group and a (deuterated alkyl)aminocarbonyl group.
3. The composition according to claim 2, wherein R 1 is phenyl substituted by one, two or three substituents selected from the group consisting of: C 1-4 Alkylsulfonyl, C 1-4 Alkoxy, C 1-4 Alkylaminocarbonyl, deuterated C 1-4 Alkoxy and (deuterated C 1-4 alkyl)aminocarbonyl.
4. The composition according to claim 3, wherein R 1 is phenyl substituted by one, two or three substituents selected from the group consisting of methylsulfonyl, methoxy, methylaminocarbonyl, trideuteromethoxy or (trideuteromethyl)aminocarbonyl.
5. The composition according to claim 1, wherein R 2 It is an alkyl group which is unsubstituted or substituted by a halogen group.
6. The composition according to claim 5, wherein R 2 It is C 1-4 Halogenated alkyl.
7. The composition according to claim 6, wherein R 2 It is 1,1,1-trifluoroethyl.
8. The composition according to claim 1, wherein R 4 is 4-piperidinyl which is unsubstituted or substituted by one, two or three substituents selected from the group consisting of halogen, C 1-4 Alkyl and C 1-4 Alkoxy-(hydroxy)-C 1-4 alkyl.
9. The composition according to claim 8, wherein R 4 is 4-piperidinyl substituted with fluorine and one or two further substituents selected from the group consisting of methyl, trideuteromethyl, tert-butyl, 2-hydroxy-methoxypropyl and 2-hydroxy-trideuteromethoxypropyl.
10. The composition according to claim 1, having the formula: in: -R 2 is a C1-C4 haloalkyl group, -R 25 is selected from hydrogen, hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, alkylsulfonyl, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, Haloalkynyl, alkoxy, deuterated alkoxy, aryl, aryloxy, aralkyl, arylalkoxy groups, heterocyclic groups, acyl groups, acyloxy groups, carbamate groups, amide groups, deuterated alkylamide groups, urea groups, epoxy groups, and ester groups; -R 26 is selected from the group consisting of a hydrogen group, a hydroxyl group, a sulfhydryl group, a halogen group, an amino group, a nitro group, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a haloalkyl group, an alkenyl group, a haloalkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, a deuterated alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, a deuterated amide group, a urea group, an epoxy group, and an ester group; -R 27 A hydrogen group substituted by: hydroxyl, thiol, halogen, amino, nitro, a nitroso group, a cyano group, an azido group, a sulfoxide group, a sulfone group, a sulfonamide group, a carboxyl group, a carboxaldehyde group, an imine group, an alkyl group, a halogenated alkyl group, an alkenyl group, a halogenated alkenyl group, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, urea, epoxy and ester groups; -R 28 is selected from the group consisting of hydrogen, hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, deuterated alkyl, halogenated alkyl, alkenyl, halogenated alkenyl, an alkynyl group, a haloalkynyl group, an alkoxy group, an aryl group, an aryloxy group, an aralkyl group, an arylalkoxy group, a heterocyclic group, an acyl group, an acyloxy group, a carbamate group, an amide group, urea, epoxy and ester groups; The condition is R 25 , R 26 , R 27 or R 28 One or more of is a deuterated group; or a pharmaceutically acceptable salt thereof.
11. The composition according to claim 10, wherein: -R 2 It is 1,1,1-trifluoroethyl; -R 25 is selected from C1-C4 alkylaminocarbonyl, deuterated C1-C4 alkylaminocarbonyl or C1-C4 alkylsulfonyl; -R 26 is C1-C4 alkoxy or deuterated C1-C4 alkoxy; -R 27 is a hydrogen radical or a fluorine radical; and -R 28 It is selected from C1-C4 alkyl, deuterated C1-C4 alkyl, C1-C4 alkoxy-C1-C4 alkyl optionally substituted with hydroxyl, or deuterated C1-C4 alkoxy-C1-C4 alkyl optionally substituted with hydroxyl.
12. The composition according to claim 11, wherein: -R 25 is methylsulfonyl, methylaminocarbonyl or trideuterated methylaminocarbonyl; -R 26 is methoxy or trideuterated methoxy; and -R 28 It is selected from methyl, tert-butyl, deuterated methyl, 2-hydroxy-1-methoxypropyl or 1-trideuterated methoxy-2-hydroxypropyl.
13. The composition of claim 10, wherein the composition has the formula:
14. A composition according to any one of claims 1-13, wherein at least about 25%, at least about 50%, at least about 75%, at least about 82.5%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% of the molecules in the population of molecules each independently contain deuterium atoms.
15. The composition of any one of claims 1-13, wherein at least about 95% of the molecules in the population of molecules each independently comprise a deuterium atom.
16. The composition of any one of claims 1-13, wherein at least about 97% of the molecules in the population of molecules each independently comprise a deuterium atom.
17. A method of inducing apoptosis in a cell, the method comprising contacting the cell with a therapeutically effective amount of the composition according to any one of claims 1-16.
18. The method of claim 17, wherein the compound of formula (I) increases the ability of the p53 mutant to bind to DNA.
19. The method of claim 17, wherein the p53 mutant is p53Y220C.
20. The method of claim 17, wherein the compound of formula (I) induces a conformational change in the p53 mutant.
21. The method of claim 17, wherein the compound of formula (I) increases the stability of the biologically active conformation of the p53 mutant relative to the stability of the biologically active conformation of the p53 mutant in the absence of the compound of formula (I).
22. A method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a composition according to any one of claims 1 to 16, wherein the compound of formula (I) has a SC of less than 1 mM for p53 Y220C. 150 Values, as measured by homogeneous time-resolved fluorescence (HTRF) assay.
23. The method of claim 22, wherein the administration is intravenous.
24. The method of claim 22, wherein the administration is oral administration.
25. The method of claim 22, wherein the administration is intratumoral administration.
26. The method of claim 22, wherein the therapeutically effective amount is about 20 mg / kg to about 400 mg / kg.
27. The method of claim 22, wherein the cancer is breast cancer.
28. The method of claim 22, wherein the cancer is lung cancer.
29. The method of claim 22, wherein the compound of formula (I) increases the stability of the biologically active conformation of the p53 mutant relative to the stability of the biologically active conformation of the p53 mutant in the absence of the compound of formula (I).
30. The method of claim 22, wherein the compound of formula (I) has a SC of less than about 50 nM. 150 value.
Citation Information
Patent Citations
METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
US20170240525A1
METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
US20220315564A1
